<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005162.pub4" GROUP_ID="LIVER" ID="196903093010273978" MERGED_FROM="" MODIFIED="2017-06-14 11:27:43 +0100" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="MK01" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2017-06-14 10:06:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2017-04-25 15:07:03 +0100" MODIFIED_BY="[Empty name]">Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome</TITLE>
<CONTACT>
<PERSON ID="A370F19282E26AA201ACDCB9FCA63E18" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Lise Lotte</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>MD, DMSc</SUFFIX>
<POSITION>Consultant</POSITION>
<EMAIL_1>liselottegluud@yahoo.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+45 38621964</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Gastrounit, Medical Division</DEPARTMENT>
<ORGANISATION>Copenhagen University Hospital Hvidovre</ORGANISATION>
<ADDRESS_1>Kettegaards Alle</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hvidovre</CITY>
<ZIP>2650</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 38621964</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-06-14 10:06:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="z1509071328086502854147333323401" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Andrew</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Allegretti</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>AALLEGRETTI@PARTNERS.ORG</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Nephrology, Department of Medicine</DEPARTMENT>
<ORGANISATION>Massachusetts General Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Boston</CITY>
<ZIP>MA 02114</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1308070916599805791887685003564" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Mads</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Israelsen</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>mads@engolf.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Gastroenterology and Hepatology</DEPARTMENT>
<ORGANISATION>Odense University Hospital</ORGANISATION>
<ADDRESS_1>Sdr. Boulevard 29</ADDRESS_1>
<ADDRESS_2/>
<CITY>Odense C</CITY>
<ZIP>5000</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="A30CDA7B82E26AA200538793298BD082" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Aleksander</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Krag</LAST_NAME>
<SUFFIX/>
<POSITION>Professor, Consultant</POSITION>
<EMAIL_1>aleksanderkrag@hotmail.com</EMAIL_1>
<EMAIL_2>aleksanderkrag@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE>21409915</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Gastroenterology and Hepatology</DEPARTMENT>
<ORGANISATION>Odense University Hospital</ORGANISATION>
<ADDRESS_1>Sdr. Boulevard 29, indgang 126</ADDRESS_1>
<ADDRESS_2/>
<CITY>Odense C</CITY>
<ZIP>5000</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 21409915</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1509071330355513212479141475239" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Manol</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jovani</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical and Translational Epidemiology Unit</POSITION>
<EMAIL_1>maj082@mail.harvard.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Gastroenterology</DEPARTMENT>
<ORGANISATION>Massachusetts General Hospital and Harvard Medical School</ORGANISATION>
<ADDRESS_1>55 Fruit St</ADDRESS_1>
<ADDRESS_2/>
<CITY>Boston</CITY>
<ZIP>MA 02114</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1509071349513409256835507490251" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alison</FIRST_NAME>
<MIDDLE_INITIALS>H</MIDDLE_INITIALS>
<LAST_NAME>Goldin</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>AGOLDIN@PARTNERS.ORG</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Gastroenterology, Hepatology and Endoscopy</DEPARTMENT>
<ORGANISATION>Brigham and Women's Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Boston</CITY>
<ZIP>MA 02115</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1509071351565729458951352624075" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Allison</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Schulman</LAST_NAME>
<SUFFIX>M.D., M.P.H.</SUFFIX>
<POSITION/>
<EMAIL_1>ARSCHULMAN@PARTNERS.ORG</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Gastroenterology, Hepatology and Endoscopy</DEPARTMENT>
<ORGANISATION>Brigham and Women's Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Boston</CITY>
<ZIP>MA 02115</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1509071354031164777985850745980" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Rachel</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>Winter</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>RWINTER1@PARTNERS.ORG</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Gastroenterology, Hepatology and Endoscopy</DEPARTMENT>
<ORGANISATION>Brigham and Women's Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Boston</CITY>
<ZIP>MA 02115</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="A370F19282E26AA201ACDCB9FCA63E18" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Lise Lotte</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>MD, DMSc</SUFFIX>
<POSITION>Consultant</POSITION>
<EMAIL_1>liselottegluud@yahoo.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+45 38621964</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Gastrounit, Medical Division</DEPARTMENT>
<ORGANISATION>Copenhagen University Hospital Hvidovre</ORGANISATION>
<ADDRESS_1>Kettegaards Alle</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hvidovre</CITY>
<ZIP>2650</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 38621964</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2017-01-31 14:28:27 +0000" MODIFIED_BY="Sarah  Klingenberg">
<UP_TO_DATE>
<DATE DAY="20" MONTH="6" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="11" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="12" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-06-14 09:38:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-06-14 09:38:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="17" MONTH="2" YEAR="2016"/>
<DESCRIPTION>
<P>Based on peer review comments, the outcomes now include health-related quality of life and the total number of serious adverse events. We now only include trials with a placebo or no intervention comparison. Trials with active comparators are included in a separate review (<LINK REF="REF-Israelsen-2015a" TYPE="REFERENCE">Israelsen 2015a</LINK>). We have updated the methods based on the latest recommendations from Cochrane and the Cochrane Hepato-Biliary Group. The updates include the statistical analyses and the bias assessment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-06-14 09:37:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="17" MONTH="2" YEAR="2016"/>
<DESCRIPTION>
<P>We included three additional randomised clinical trials (RCTs). Our overall conclusions did not change.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-08-20 13:19:25 +0100" MODIFIED_BY="Dimitrinka Nikolova"/>
<SOURCES_OF_SUPPORT MODIFIED="2010-10-28 16:08:30 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-10-28 16:08:13 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-10-28 16:08:13 +0100" MODIFIED_BY="[Empty name]">
<NAME>No internal funding received</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-10-28 16:08:30 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-10-28 16:08:30 +0100" MODIFIED_BY="[Empty name]">
<NAME>No external funding received</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-06-14 10:06:59 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2017-06-14 10:02:30 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2016-07-26 13:50:29 +0100" MODIFIED_BY="[Empty name]">Terlipressin versus placebo/no intervention for people with cirrhosis and hepatorenal syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2017-05-31 12:28:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Background </B>
</P>
<P>Cirrhosis is a chronic disorder of the liver where scar tissue replaces the normal liver. People with cirrhosis can develop a kidney disease known as hepatorenal syndrome. The disease may develop when the blood flow to the kidneys becomes insufficient. Increasing the blood flow to the kidneys may therefore benefit people with hepatorenal syndrome. There are two types of hepatorenal syndrome: type 1 occurs rapidly, and type 2 has a slower onset. Terlipressin is a drug that increases the blood flow to the kidneys by constricting blood vessels. The drug may therefore help people with cirrhosis and hepatorenal syndrome.</P>
<P>
<B>Review question </B>
</P>
<P>Is terlipressin better than inactive placebo/no treatment for people with hepatorenal syndrome?</P>
<P>
<B>Search date</B>
</P>
<P>November 2016.</P>
<P>
<B>Study characteristics </B>
</P>
<P>The review includes nine randomised clinical trials (RCTs) and a total of 534 participants. The trials originated from six countries. Seven trials included only participants with type 1 hepatorenal syndrome. Two trials included a total of 96 participants with type 1 or type 2 hepatorenal syndrome.</P>
<P>
<B>Study funding sources </B>
</P>
<P>Three RCTs reported funding from a pharmaceutical company. The remaining trials did not report funding or did not receive funding from pharmaceutical companies.</P>
<P>
<B>Key results </B>
</P>
<P>People who received terlipressin had a lower risk of dying than people who received inactive placebo or no treatment. Terlipressin was also associated with a beneficial effect on renal function. Terlipressin increased the risk of serious circulation and heart problems (so-called cardiovascular events). Other adverse events included diarrhoea and abdominal pain.</P>
<P>The analyses mainly included people with type 1 hepatorenal syndrome. No beneficial or harmful effects of terlipressin were found when analysing participants with type 2 hepatorenal syndrome (possibly due to the small number of participants).</P>
<P>
<B>Quality of the evidence </B>
</P>
<P>We considered the evidence to be of low quality.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-06-14 10:01:05 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ABS_BACKGROUND MODIFIED="2017-03-15 11:10:02 +0000" MODIFIED_BY="[Empty name]">
<P>Hepatorenal syndrome is a potentially reversible renal failure associated with severe liver disease. The disease is relatively common among people with decompensated cirrhosis. Terlipressin is a drug that increases the blood flow to the kidneys by constricting blood vessels. The previous version of this systematic review found a potential beneficial effect of terlipressin on mortality and renal function in people with cirrhosis and hepatorenal syndrome. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-02-18 16:33:48 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the beneficial and harmful effects of terlipressin versus placebo/no intervention for people with cirrhosis and hepatorenal syndrome.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-06-13 17:38:47 +0100" MODIFIED_BY="[Empty name]">
<P>We identified eligible trials through searches of the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE, Embase, and Science Citation Index Expanded, and manual searches until 21 November 2016.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-05-31 10:42:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trials (RCTs) involving participants with cirrhosis and type 1 or type 2 hepatorenal syndrome allocated to terlipressin versus placebo or no intervention. We allowed co-administration with albumin administered to both comparison groups.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-06-14 09:50:12 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Two review authors independently extracted data from trial reports and undertook correspondence with the authors. Primary outcomes were mortality, hepatorenal syndrome, and serious adverse events. We conducted sensitivity analyses of RCTs in which participants received albumin, subgroup analyses of participants with type 1 or type 2 hepatorenal syndrome, and Trial Sequential Analyses to control random errors. We reported random-effects meta-analyses with risk ratios (RR) and 95% confidence intervals (CI). We assessed the risk of bias based on the Cochrane Hepato-Biliary Group domains. We graded the quality of the evidence using GRADE.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-06-14 10:01:05 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included nine RCTs with a total of 534 participants with cirrhosis and ascites. One RCT had a low risk of bias for mortality and a high risk of bias for the remaining outcomes. All included trials had a high risk of bias for non-mortality outcomes. In total, 473 participants had type 1 hepatorenal syndrome. Seven RCTs specifically evaluated terlipressin and albumin. Terlipressin was associated with a beneficial effect on mortality when including all RCTs (RR 0.85, 95% CI 0.73 to 0.98; 534 participants; number needed to treat for an additional beneficial outcome (NNTB) 10.3 people; low-quality evidence). Trial Sequential Analysis including all RCTs also found a beneficial effect of terlipressin. Additional analyses showed a beneficial effect of terlipressin and albumin on reversal of hepatorenal syndrome (RR 0.63, 95% CI 0.48 to 0.82; 510 participants; 8 RCTs; NNTB 4 people; low-quality evidence). Terlipressin increased the risk of serious cardiovascular adverse events (RR 7.26, 95% CI 1.70 to 31.05; 234 participants; 4 RCTs), but it had no effect on the risk of serious adverse events when analysed as a composite outcome (RR 0.91, 95% CI 0.68 to 1.21; 534 participants; 9 RCTs; number needed to treat for an additional harmful outcome 24.5 people; low-quality evidence). Non-serious adverse events were mainly gastrointestinal, including diarrhoea (RR 5.76, 95% CI 2.19 to 15.15; 240 participants; low-quality evidence) and abdominal pain (RR 1.54, 95% CI 0.97 to 2.43; 294 participants; low-quality evidence).</P>
<P>We identified one ongoing trial on terlipressin versus placebo in participants with cirrhosis, ascites, and hepatorenal syndrome type 1.</P>
<P>Three RCTs reported funding from a pharmaceutical company. The remaining trials did not report funding or did not receive funding from pharmaceutical companies.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-06-14 09:52:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>This review suggests that terlipressin may be associated with beneficial effects on mortality and renal function in people with cirrhosis and type 1 hepatorenal syndrome, but it is also associated with serious adverse effects. We downgraded the strength of the evidence due to methodological issues including bias control, clinical heterogeneity, and imprecision. Consequently, additional evidence is needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-06-14 10:02:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<BACKGROUND MODIFIED="2017-05-31 12:28:12 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2017-05-31 12:28:12 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatorenal syndrome is a potentially reversible renal failure associated with severe liver disease (<LINK REF="REF-Arroyo-1996" TYPE="REFERENCE">Arroyo 1996</LINK>). The disease is relatively common among people with decompensated cirrhosis. Over 20% of people with decompensated cirrhosis become hospitalised with renal failure, among whom up to 20% have hepatorenal syndrome (<LINK REF="REF-Gines-1993" TYPE="REFERENCE">Gines 1993</LINK>; <LINK REF="REF-Garcia_x002d_Tsao-2008" TYPE="REFERENCE">Garcia-Tsao 2008</LINK>; <LINK REF="REF-Israelsen-2015b" TYPE="REFERENCE">Israelsen 2015b</LINK>). The diagnosis includes cirrhosis and ascites plus impaired renal function after exclusion of parenchymal renal disease and factors that may precipitate renal dysfunction in cirrhosis (<LINK REF="REF-Salerno-2007" TYPE="REFERENCE">Salerno 2007</LINK>). Hepatorenal syndrome is divided into two types, with type 1 having the most rapid course of development. Without treatment, type 1 has a median survival of about two weeks and type 2 a median survival of about six months (<LINK REF="REF-Arroyo-1996" TYPE="REFERENCE">Arroyo 1996</LINK>; <LINK REF="REF-Gines-2003" TYPE="REFERENCE">Gines 2003</LINK>; <LINK REF="REF-Salerno-2007" TYPE="REFERENCE">Salerno 2007</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-02-18 17:08:20 +0000" MODIFIED_BY="[Empty name]">
<P>The development of hepatorenal syndrome is associated with the circulatory changes seen in cirrhosis of the liver subsequent to portal hypertension and vasodilation of the splanchnic vasculature (<LINK REF="REF-Cardenas-2003" TYPE="REFERENCE">Cardenas 2003</LINK>). This vasodilation results in effective underfilling of the renal arteries and activation of the renin-angiotensin-aldosterone, the arginine-vasopressin, and the sympathetic nervous systems (<LINK REF="REF-Pasqualetti-1998" TYPE="REFERENCE">Pasqualetti 1998</LINK>; <LINK REF="REF-Moller-2004" TYPE="REFERENCE">Moller 2004</LINK>; <LINK REF="REF-Ruiz-del-Arbol-2005" TYPE="REFERENCE">Ruiz del Arbol 2005</LINK>). Activation of these systems may in turn lead to severe vasoconstriction of the renal arteries and hepatorenal syndrome (<LINK REF="REF-Cardenas-2003" TYPE="REFERENCE">Cardenas 2003</LINK>). Current treatments focus on improvement of renal blood flow and effective arterial circulation. This is done with volume expanders (such as intravenous albumin) or with vasoactive drugs that preferentially constrict the splanchnic circulation, such as terlipressin.</P>
</INTERVENTION>
<THEORY MODIFIED="2017-05-08 15:15:05 +0100" MODIFIED_BY="[Empty name]">
<P>Vasoactive drugs that increase the splanchnic arterial tone may reverse hepatorenal syndrome. Vasopressin is a potential candidate, but may lead to severe ischaemia of the mesenteric mucosa, skin, and myocardium (<LINK REF="REF-Obritsch-2004" TYPE="REFERENCE">Obritsch 2004</LINK>). A controlled trial found that the vasopressin analogue terlipressin may be a safer alternative (<LINK REF="REF-Freeman-1982" TYPE="REFERENCE">Freeman 1982</LINK>). Terlipressin is administered intravenously either by bolus or continuous infusion. It is commonly titrated based on desired change in mean arterial pressure. It has both systemic and splanchnic constrictive effects, so adverse events include sequelae of vasoconstriction, such as mild gastrointestinal symptoms (e.g. diarrhoea and abdominal pain) or more severe evidence of ischaemia.</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-05-31 10:55:42 +0100" MODIFIED_BY="[Empty name]">
<P>Two initial randomised clinical trials (RCTs) evaluated terlipressin for participants with hepatorenal syndrome; however, they were small and had short-term follow-up (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>). Three subsequent larger RCTs found no convincing effects on mortality (<LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>). Three meta-analyses of RCTs and observational studies reached equivocal findings (<LINK REF="REF-Fabrizi-2009" TYPE="REFERENCE">Fabrizi 2009</LINK>; <LINK REF="REF-Dobre-2010" TYPE="REFERENCE">Dobre 2010</LINK>; <LINK REF="REF-Sagi-2010" TYPE="REFERENCE">Sagi 2010</LINK>). In the previous version of this systematic review, we found a potential beneficial effect of terlipressin on mortality and reversal of hepatorenal syndrome (<LINK REF="REF-Gluud-2006" TYPE="REFERENCE">Gluud 2006</LINK>), but we also identified potential methodological concerns. We updated the review to include the currently available evidence.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-05-08 15:15:41 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the beneficial and harmful effects of terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-06-14 10:02:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SELECTION_CRITERIA MODIFIED="2017-06-14 09:50:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2017-05-31 10:56:09 +0100" MODIFIED_BY="[Empty name]">
<P>We included RCTs irrespective of blinding, publication status, or language. We included the first period from cross-over RCTs. In addition, we planned to include quasi-randomised studies and observational studies in our assessment of serious adverse events (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), although this is a known limitation making us focus more on benefits than on harms (<LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-01-17 13:18:28 +0000" MODIFIED_BY="[Empty name]">
<P>We included people with cirrhosis and type 1 or type 2 hepatorenal syndrome (defined as an increase in creatinine in people with ascites and no other causes of renal disease).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-05-31 10:56:14 +0100" MODIFIED_BY="[Empty name]">
<P>We included RCTs comparing terlipressin (any dose or duration) versus placebo or no intervention. We allowed co-administration of albumin given to both comparison groups.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-06-14 09:50:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We assessed all outcomes at the maximum duration of follow-up.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-05-31 10:56:24 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Mortality.</LI>
<LI>Hepatorenal syndrome (number of participants who did not achieve reversal of hepatorenal syndrome).</LI>
<LI>Serious adverse events: any untoward medical occurrence that led to death, was life-threatening, or required hospitalisation or prolongation of hospitalisation (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>). We analysed serious adverse events as a composite outcome (<LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-06-14 09:50:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<OL>
<LI>Health-related quality of life: the overall score based on the quality of life questionnaires used in individual trials.</LI>
<LI>Non-serious adverse events: all adverse events that did not fulfil the criteria for serious adverse events.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-06-14 10:00:00 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ELECTRONIC_SEARCHES MODIFIED="2017-06-14 09:41:09 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We performed electronic searches in the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE (OvidSP), Embase (OvidSP), and Science Citation Index Expanded (Web of Science) (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>). The search strategies with the timespan of the searches are given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. We updated searches as of 21 November 2016.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-06-14 10:00:00 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Manual searches included scanning of reference lists in relevant articles and conference proceedings. We also searched trial registers through the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) search portal (<A HREF="http://www.who.int/ictrp/search/en/">www.who.int/ictrp/search/en/</A>) (21 November, 2016).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-06-14 10:02:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_SELECTION MODIFIED="2017-05-31 11:50:32 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (AA and MI) independently selected trials eligible for inclusion from the updated literature searches and listed excluded with the reasons for exclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-05-31 11:01:18 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (AA and MI) independently extracted data. All disagreements were resolved through discussion before analyses. In case of disagreements, a third review author (LG) acted as ombudsman. We wrote to authors of the included trials to obtain additional information not described in the published reports, including missing data.<BR/>
</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-05-31 12:28:31 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias using the domains described in the Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation sequence generation</HEADING>
<UL>
<LI>Low risk of bias: the study authors performed sequence generation using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if an independent person not otherwise involved in the study performed them.</LI>
<LI>Unclear risk of bias: not specified.</LI>
<LI>High risk of bias: the sequence generation was not random. We planned to include such studies for assessment of harms.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g. if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes).</LI>
<LI>Unclear risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.</LI>
<LI>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants and personnel</HEADING>
<UL>
<LI>Low risk of bias: i) the outcome was mortality, which according to previous empirical evidence is not likely to be influenced by lack of blinding (<LINK REF="REF-Hr_x00f3_bjartsson-2001" TYPE="REFERENCE">Hróbjartsson 2001</LINK>; <LINK REF="REF-Savovi_x0107_-2012" TYPE="REFERENCE">Savovi&#263; 2012</LINK>); or ii) blinding of participants and key study personnel ensured, and it is unlikely that the blinding could have been broken.</LI>
<LI>Unclear risk of bias: insufficient information to permit judgement of &#8216;low risk&#8217; or &#8216;high risk&#8217;.</LI>
<LI>High risk of bias: no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding (non-mortality outcomes).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of outcome assessors</HEADING>
<UL>
<LI>Low risk of bias: i) the outcome was mortality, which according to previous empirical evidence is not likely to be influenced by lack of blinding (<LINK REF="REF-Hr_x00f3_bjartsson-2001" TYPE="REFERENCE">Hróbjartsson 2001</LINK>; <LINK REF="REF-Savovi_x0107_-2012" TYPE="REFERENCE">Savovi&#263; 2012</LINK>); or ii) blinding of outcome assessment ensured, and it is unlikely that the blinding could have been broken.</LI>
<LI>Unclear risk of bias: insufficient information to permit judgement of &#8216;low risk&#8217; or &#8216;high risk&#8217;.</LI>
<LI>High risk of bias: no blinding or inadequate blinding (e.g. intravenous versus orally administered drugs), and the outcome is likely to be influenced by lack of blinding (non-mortality outcomes).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. The investigators used sufficient methods, such as intention-to-treat analyses with multiple imputations or carry-forward analyses, to handle missing data.</LI>
<LI>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data induced bias on the results.</LI>
<LI>High risk of bias: the results were likely to be biased due to missing data.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk of bias: the trial reported clinically relevant outcomes (mortality, hepatic encephalopathy, and serious adverse events). If we had access to the original trial protocol, the outcomes should have been those called for in that protocol. If we obtained information from a trial registry (such as <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>), we only used the information if the investigators registered the trial before inclusion of the first participant.</LI>
<LI>Unclear risk of bias: predefined outcomes were not reported fully.</LI>
<LI>High risk of bias: one or more predefined outcomes were not reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For-profit bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appears to be free of industry sponsorship or other type of for-profit support.</LI>
<LI>Unclear risk of bias: no information on clinical trial support or sponsorship was available.</LI>
<LI>High risk of bias: the trial was sponsored by industry, received support in the form of terlipressin or placebo, or received any other type of support.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of other biases including medicinal dosing problems or follow-up (as defined below).</LI>
<LI>Unclear risk of bias: the trial may or may not have been free of other factors that could put it at risk of bias.</LI>
<LI>High risk of bias: there were other factors in the trial that could put it at risk of bias, such as the administration of inappropriate treatments to the controls (e.g. an inappropriate dose) or follow-up (e.g. the trial included different follow-up schedules for participants in the allocation groups), or premature discontinuation of the trial.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Overall bias assessment</HEADING>
<UL>
<LI>Low risk of bias: all domains were classified as low risk of bias using the definitions described above.</LI>
<LI>High risk of bias: one or more of the bias domains were classified as unclear or high risk of bias.</LI>
</UL>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-05-31 12:28:32 +0100" MODIFIED_BY="[Empty name]">
<P>We expressed outcomes using risk ratios (RR) with 95% confidence intervals (CI). For primary outcomes, we calculated the number needed to treat (NNT) using the inverse of the risk difference (RD). Based on the control group event rate, we repeated the analyses using odds ratios (OR) and RD. The analyses using OR and RD had no influence on the results of the review.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-02-18 17:22:02 +0000" MODIFIED_BY="[Empty name]">
<P>We included data from the first treatment period of cross-over trials.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-05-31 12:28:34 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to evaluate the importance of missing data in a worst-case scenario analysis (with inclusion of missing outcomes as treatment failures) and an extreme worst-case scenario analysis (including missing outcomes as failures in the experimental group and successes in the control group). However, we did not identify participants with missing outcome data and were therefore unable to conduct these analyses.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-05-31 11:02:00 +0100" MODIFIED_BY="[Empty name]">
<P>We expressed heterogeneity as I<SUP>2 </SUP>values using the following thresholds: 0% to 40% (unimportant), 40 to 60% (moderate), 60 to 80% (substantial), and &gt; 80% (considerable). We have included this information in the 'Summary of findings' tables (<LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-05-31 11:02:10 +0100" MODIFIED_BY="[Empty name]">
<P>For meta-analyses with at least 10 RCTs, we planned to assess reporting biases through regression analyses.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-06-14 10:02:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We performed the analyses in Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), <LINK REF="REF-STATA" TYPE="REFERENCE">STATA</LINK> (<LINK REF="REF-STATA" TYPE="REFERENCE">STATA</LINK>), and Trial Sequential Analysis (<LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>), and used <LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK> softwareto prepare 'Summary of findings' tables (<LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Meta-analysis</HEADING>
<P>We initially conducted fixed-effect and random-effects meta-analyses (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If the estimates of the fixed-effect and random-effects meta-analyses were similar, then we assumed that any small-study effects had little effect on the intervention effect estimate. If the random-effects estimate was more beneficial, we planned to re-evaluate whether it was reasonable to conclude that the intervention was more effective in the smaller studies. We originally planned to evaluate if the larger RCTs tended to be conducted with greater methodological rigour, or conducted in circumstances more typical of the use of terlipressin in clinical practice. Had we found this scenario, we planned to report the results of meta-analyses restricted to the larger, more rigorous studies. However, this scenario did not occur.</P>
<P>Based on the expected clinical heterogeneity, we expected that a number of analyses would display statistical heterogeneity (I<SUP>2 </SUP>&gt; 0%). For random-effects models, precision will decrease with increasing heterogeneity and confidence intervals will widen correspondingly. We therefore expected that the random-effects model would give the most conservative (and a more correct) estimate of the intervention effect. Accordingly, we have reported the results of our analyses based on random-effects meta-analyses.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trial Sequential Analysis</HEADING>
<P>We performed Trial Sequential Analysis to control the risks of type 1 and type 2 errors and to evaluate futility in the assessment of our primary outcomes (<LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>; <LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>). We defined the required information size (also known as the diversity-adjusted required information size) as the number of participants needed to detect or reject an intervention effect based on the relative risk reduction (RRR) and control group risk (CGR). Firm evidence was established if the Z-curve crossed the monitoring boundary (also known as the trial sequential monitoring boundary) before reaching the required information size. Based on previous evidence (<LINK REF="REF-Krag-2008" TYPE="REFERENCE">Krag 2008</LINK>), we performed the analyses with alpha set to 3%, power to 90%, and the RRR, CGR, and heterogeneity correction to 25%, 61.5%, and 30% for mortality; 25%, 87.5%, and 70% for hepatorenal syndrome; and 25%, 15%, and 20% for serious cardiovascular adverse events. We repeated the analyses with the RRR reduced to 20% for mortality, hepatorenal syndrome, and serious cardiovascular adverse events. In the analyses of serious cardiovascular events, we also reduced the CGR to 5%.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-02-18 17:29:21 +0000" MODIFIED_BY="[Empty name]">
<P>We conducted subgroup analyses to investigate heterogeneity associated with the type of hepatorenal syndrome and use of albumin. </P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-06-14 10:02:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We did not evaluate the influence of bias because only one RCT was at low risk of bias for mortality and no randomised clinical trials were at low risk of bias for the remaining outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings tables</HEADING>
<P>We used <LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK> to generate a 'Summary of findings' table with information about outcomes, risk of bias, and the results of the meta-analyses (<LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK>). We used the GRADE system to evaluate the quality of the evidence for outcomes reported in the review considering the within-study risk of bias (methodological quality), indirectness of evidence, heterogeneity, imprecision of effect estimate, and risk of publication bias.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-06-14 10:02:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_DESCRIPTION MODIFIED="2017-06-12 07:21:34 +0100" MODIFIED_BY="[Empty name]">
<P>We included nine randomised clinical trials in the quantitative and qualitative analyses (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). We also identified one ongoing trial (<LINK REF="STD-NCT01143246" TYPE="STUDY">NCT01143246</LINK>).</P>
<SEARCH_RESULTS MODIFIED="2017-05-31 12:28:42 +0100" MODIFIED_BY="[Empty name]">
<P>The electronic searches revealed 619 potentially eligible references and the manual searches three additional references (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). After scanning the titles and abstracts, we retrieved and listed 25 records. We had to exclude 10 of these that referred to randomised clinical trials on participants with hepatorenal syndrome because they did not evaluate the interventions assessed in the present review (<LINK REF="STD-Chelarescu-2003" TYPE="STUDY">Chelarescu 2003</LINK>; <LINK REF="STD-Pomier-2003" TYPE="STUDY">Pomier 2003</LINK>; <LINK REF="STD-Alessandria-2007" TYPE="STUDY">Alessandria 2007</LINK>; <LINK REF="STD-Angeli-2008" TYPE="STUDY">Angeli 2008</LINK>; <LINK REF="STD-Sharma-2008" TYPE="STUDY">Sharma 2008</LINK>; <LINK REF="STD-Silawat-2011" TYPE="STUDY">Silawat 2011</LINK>; <LINK REF="STD-Cavallin-2012" TYPE="STUDY">Cavallin 2012</LINK>; <LINK REF="STD-Indrabi-2013" TYPE="STUDY">Indrabi 2013</LINK>; <LINK REF="STD-Wan-2014" TYPE="STUDY">Wan 2014</LINK>; <LINK REF="STD-Cavallin-2015" TYPE="STUDY">Cavallin 2015</LINK>; <LINK REF="STD-Nguyen_x002d_Tat-2015" TYPE="STUDY">Nguyen-Tat 2015</LINK>). The remaining references referred to nine RCTs that fulfilled our inclusion criteria (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>; <LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>). One trial used a cross-over design (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>), and the remaining a parallel-group design (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-06-12 07:21:34 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Trial characteristics</HEADING>
<P>One RCT was published in abstract form (<LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>) and the remaining RCTs as full-paper articles (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The language of trial publications was Chinese (<LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>), Italian (<LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>), or English (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>). The trials were conducted in the United States, Italy, Spain, Canada, India, China, Germany, and Russia. The trial investigators performed the trials in specialised units in an intensive or semi-intensive setting. Three trials were multicenter trials (<LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>), and the remaining trials were single-centre trials (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>; <LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>).</P>
<P>The duration of follow-up was six months in two trials (<LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>), three months in one RCT (<LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>), and end of treatment in the remaining trials (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>; <LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participant characteristics</HEADING>
<P>The total number of participants was 534 participants. Included participants had cirrhosis, ascites, and hepatorenal syndrome with serum creatinine &gt; 133 µmol/L (1.5 mg/dL) after diuretic withdrawal and volume expansion. None of the participants had evidence of shock, parenchymal renal disease, treatment with nephrotoxic drugs, or other potential causes of kidney disease. In total, 473 participants had type 1 hepatorenal syndrome. One RCT included 11 participants with type 2 hepatorenal syndrome (<LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>). One RCT with 50 participants did not describe if participants had type 1 or type 2 hepatorenal syndrome (<LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>). The mean age in the terlipressin and control groups ranged from 51 to 59 years and 52 to 60 years. The proportion of men ranged from 40% to 71%, and the proportion with alcoholic liver disease from 13% to 72%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention characteristics</HEADING>
<P>The median initial dose of terlipressin was 1 mg four times daily. The RCTs used a fixed dose of terlipressin (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>; <LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>), or increased the dose after three days in non-responders to a maximum of 2 mg four to six times daily (<LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>). One trial used continuous administration of terlipressin for the first day before switching to bolus dosing (<LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>). The duration of terlipressin administration ranged from two days, in <LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>, to 19 days, in <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>, with a median treatment duration of 15 days. Two trials did not use albumin (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>). All participants in the experimental and control groups of the remaining trials received comparable albumin (<LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-05-31 11:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>The excluded RCTs compared terlipressin and albumin versus other vasoactive drugs for hepatorenal syndrome (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-06-14 09:58:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We identified several sources of bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). For the outcome mortality, we classified one trial as at 'low risk of bias' <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>, and the remaining trials as at 'high risk of bias' (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>; <LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>). For non-mortality outcomes, we classified all RCTs as at 'high risk of bias'. No single study lacked bias across all assessed domains, including randomisation/sequence allocation, blinding, and for-profit funding sources. We deemed <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK> as at 'low risk of bias' for mortality because its sources of bias were only around blinding, which was less likely to have an influence on a purely objective outcome like mortality.</P>
<P>
<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> presents review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
<ALLOCATION MODIFIED="2017-05-31 12:28:49 +0100" MODIFIED_BY="[Empty name]">
<P>Three RCTs did not describe the allocation sequence generation (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>), and two RCTs did not describe the allocation concealment (<LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>). Accordingly, we classified six RCTs as 'low risk' of selection bias (<LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2017-05-31 11:31:45 +0100" MODIFIED_BY="[Empty name]">
<P>We considered tree RCTs that were double-blind as as 'low risk' of performance and detection bias (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>). We assessed the remaining RCTsas 'unclear', <LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>, or 'high risk' of performance and detection bias (<LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>; <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-05-31 11:11:30 +0100" MODIFIED_BY="[Empty name]">
<P>Six RCTs had no missing outcome data and included all participants in the analyses (<LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>). We classified these RCTs as low risk of attrition bias and the remaining three RCTs as 'unclear risk', <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>, <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>, or 'high risk' of attrition bias (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-05-31 11:12:13 +0100" MODIFIED_BY="[Empty name]">
<P>All RCTs reported clinically relevant outcomes (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>; <LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>). We identified no discrepancies between registered protocols (for those available) and trial publications.</P>
<SUBSECTION>
<HEADING LEVEL="3">For-profit funding</HEADING>
<P>One RCT did not receive external funding (<LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>). Three RCTs received funding from a pharmaceutical company (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>). The remaining RCTs did not report funding (<LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>; <LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>).</P>
</SUBSECTION>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-05-31 12:28:51 +0100" MODIFIED_BY="[Empty name]">
<P>One study was stopped early due to low event rates (<LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-06-14 10:02:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<P>We were able to gather mortality data from all RCTs (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Terlipressin was associated with reduced mortality compared with placebo/no intervention when including all RCTs (risk ratio (RR) 0.85, 95% confidence interval (CI) 0.73 to 0.98; 534 participants; 9 RCTs; I<SUP>2</SUP> = 14%; number needed to treat for an additional beneficial outcome (NNTB) to prevent one death was 10; low-quality evidence). In Trial Sequential Analysis including all RCTs (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), the cumulative Z-curve did not cross the monitoring boundary for benefit. We planned to conduct worst-case scenario analyses. However, as six of the included RCTs did not have missing outcome data (<LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>; <LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Pulvirenti-2008" TYPE="STUDY">Pulvirenti 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>; <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>), and we were unable to extract the number of participants with missing outcomes from the remaining three RCTs (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>), we were therefore unable to conduct the analysis. Subgroup analyses found an effect of terlipressin in the RCTs evaluating type 1 hepatorenal syndrome (RR 0.78, 95% CI 0.63 to 0.98; 438 participants; 7 RCT; I<SUP>2</SUP> = 30%; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). We were unable to gather separate outcome data on participants with type 1 or type 2 hepatorenal syndrome from two RCTs (RR 0.92, 95% CI 0.75 to 1.14; 96 participants; I<SUP>2</SUP> = 0%). An additional subgroup analysis found no beneficial or harmful effect of the terlipressin and albumin (RR 0.82, 95% CI 0.67 to 1.01; 510 participants; I<SUP>2</SUP> = 22%; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Two RCTs did not report the number of participants without reversal of hepatorenal syndrome (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>). Analysis of the remaining seven RCTs showed a beneficial effect of terlipressin on this outcome measure (RR 0.63, 95% CI 0.48 to 0.82; 510 participants; I<SUP>2</SUP> = 75%; low-quality evidence; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). In Trial Sequential Analysis including these seven RCTs (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>), the cumulative Z score crossed the monitoring boundary for benefit.The NNTB to reverse one case of hepatorenal syndrome was 4. All RCTs included in this analysis evaluated terlipressin and albumin. In Trial Sequential Analysis including all RCTs regardless of bias control (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>), the cumulative Z-curve crossed the monitoring boundary for benefit. Subgroup analyses showed a beneficial effect of terlipressin on type 1 hepatorenal syndrome based on six RCTs (RR 0.64, 95% CI 0.47 to 0.87; 449 participants; I<SUP>2</SUP> = 80%), but not in participants with type 2 hepatorenal syndrome (RR 0.39, 95% CI 0.14 to 1.08; 11 participants; 1 RCT) or the trial including participants with type 1 or type 2 hepatorenal syndrome (RR 0.65, 95% CI 0.46 to 0.92; 50 participants).</P>
<P>Overall, terlipressin did not influence the risk of serious adverse events when analysed as a composite outcome (RR 0.91, 95% CI 0.68 to 1.21; participants = 534; 9 RCTs; I<SUP>2</SUP> = 71%; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The number needed to treat for an additional harmful outcome to cause one serious adverse event was 24.5. A Trial Sequential Analysis also found a detrimental effect of terlipressin on this outcome (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). As expected, the most common serious adverse events were cardiovascular (RR 7.26, 95% CI 1.70 to 31.05; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). Other serious adverse events included circulatory overload, gastrointestinal bleeding, hepatic encephalopathy, respiratory distress/acidosis, and bacterial infections.</P>
<P>We repeated the Trial Sequential Analyses with power increased to 90% and the relative risk reduction reduced to 10% for mortality and 20% for hepatorenal syndrome and serious cardiovascular adverse events. In the analyses of serious cardiovascular events, we also reduced the control group risk to 15%. All analyses found insufficient evidence to support or refute beneficial or harmful effects of terlipressin versus placebo/no intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<P>None of the included trials assessed health-related quality of life. Non-serious adverse events were similar when comparing terlipressin with placebo or no intervention (RR 1.25, 95% CI 0.58 to 2.68; 406 participants; 5 RCTs; I<SUP>2</SUP> = 17%; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). The most frequent adverse events were gastrointestinal, including abdominal pain and diarrhoea.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of the evidence</HEADING>
<P>We downgraded the quality of the evidence for all outcomes due to risk of bias, clinical heterogeneity, and imprecision according to the Trial Sequential Analyses (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-05-31 12:28:58 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2017-05-31 11:47:14 +0100" MODIFIED_BY="[Empty name]">
<P>This review found that terlipressin may reduce mortality and have a beneficial effect on renal function in type 1 hepatorenal syndrome, but an increased risk of serious cardiovascular adverse events was also noted. Other studies also show that terlipressin may be associated with severe adverse effects (<LINK REF="REF-Shawcross-2004" TYPE="REFERENCE">Shawcross 2004</LINK>; <LINK REF="REF-Krag-2008" TYPE="REFERENCE">Krag 2008</LINK>), therefore the intervention should be closely monitored. In addition, only one RCT had a low risk of bias in the overall assessment and most of the included RCTs only followed participants to the end of treatment. Accordingly, the quality of the evidence was low and additional RCTs may be needed.</P>
<P>The evidence on the use of terlipressin alone and intervention benefits in type 2 hepatorenal syndrome was scarce. Only two of the included trials assessed terlipressin alone (<LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>; <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>); the trials were small and the findings were inconclusive. Likewise, only two RCTs on terlipressin included participants with type 2 hepatorenal syndrome (<LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Zafar-2012" TYPE="STUDY">Zafar 2012</LINK>), and the number of participants with type 2 hepatorenal syndrome was relatively small. Accordingly, we identified no clear intervention effects for this patient group.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-05-31 12:28:56 +0100" MODIFIED_BY="[Empty name]">
<P>We found little evidence of clinical intertrial heterogeneity. The mean control group Child-Pugh scores were remarkably similar (11 in three trials) (<LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>). Likewise, the included trials used similar criteria to diagnose hepatorenal syndrome, based on previous recommendations (<LINK REF="REF-Arroyo-1996" TYPE="REFERENCE">Arroyo 1996</LINK>). Diagnostic criteria included presence of cirrhosis, ascites, elevated serum creatinine after at least 48 hours of diuretic withdrawal and volume expansion combined with absence of shock, treatment with nephrotoxic drugs, and parenchymal renal disease (<LINK REF="REF-Salerno-2007" TYPE="REFERENCE">Salerno 2007</LINK>). Updated criteria in 2015 now use a lower threshold of increased creatinine to diagnose hepatorenal syndrome (<LINK REF="REF-Angeli-2015" TYPE="REFERENCE">Angeli 2015</LINK>). Less emphasis is placed on the labels of type 1 hepatorenal syndrome (defined as serum creatinine increasing to 226 µmol/L (2.5 mg/dL) within two weeks) and type 2 hepatorenal syndrome (defined as a moderate to slowly progressive renal failure with serum creatinine between 133 and 226 µmol/L (1.5 to 2.5 mg/dL)). Although the included trials used previously established criteria, the evidence is likely to be applicable today. However, it may be argued that there is still room for trials on terlipressin using the current diagnostic criteria, as the current criteria are more sensitive to detection of less severe acute kidney injury. Future trials would likely benefit from adoption of a standardised treatment algorithm of terlipressin dosing and sample-sized calculations based on mortality rates, rather than rates of reversal of hepatorenal syndrome. Notably, dosing of intravenous terlipressin varied widely among studies, ranging from 1 mg twice daily, in <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>, to up to 2 mg six times per day for non-responders in <LINK REF="STD-Boyer-2016" TYPE="STUDY">Boyer 2016</LINK>, thus making direct comparisons between trials more challenging.</P>
<P>The duration of the effect of terlipressin on mortality should be considered when deciding whether or not to treat a patient with hepatorenal syndrome (<LINK REF="REF-Gluud-2010" TYPE="REFERENCE">Gluud 2010</LINK>). Some participants may die in spite of a clear improvement in renal function (<LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>). The duration of treatment varied among the included trials, ranging from two days, in <LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK>, to 19 days, in <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>, with a median duration of 15 days. This may affect the intervention effect estimates. After an initial complete normalisation of renal function, hepatorenal syndrome may reappear. We attempted to perform a post hoc analysis to determine the effect of treatment on recurrence of hepatorenal syndrome but were unable to extract the necessary data.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-05-31 11:47:50 +0100" MODIFIED_BY="[Empty name]">
<P>The present review identified a number of methodological concerns, including lack of sample size calculations, unclear randomisation, and lack of blinding. We downgraded evidence due to high risk of bias within individual trials, heterogeneity across trials, and imprecision (wide confidence intervals) of outcomes. As a result, the evidence for each of the primary and secondary analyses received a low quality rating. One of the included trials reporting sample size calculations was terminated prematurely due to unexpectedly low event rates (<LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>). The trial assessed terlipressin plus albumin versus albumin and was terminated after an interim analysis suggested that 2000 participants would be required to achieve sufficient statistical power. Whether the interim results reflect a true (low) intervention effect, a random error, or the inclusion criteria is difficult to assess. One possible explanation could be that a number of the included participants had type 2 hepatorenal syndrome; overall, there is little evidence on this patient group.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-05-31 11:51:48 +0100" MODIFIED_BY="[Empty name]">
<P>One of the main limitations of the present review concerns the relatively low overall sample size. Identification of participants who clearly fulfil the diagnostic criteria for hepatorenal syndrome may be difficult, as is the recruitment of critically ill people in clinical trials. Accordingly, the largest trials were multicentred and multinational (<LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>). This involvement of several clinical sites in more than one geographical region increases the clinical heterogeneity. On the other hand, the heterogeneity also increases the external validity, making it possible to extrapolate the results to larger patient populations in similar specialised centres. The heterogeneity increases the need for additional subgroup and sensitivity analyses. Analysis of individual patient data would have increased the possibilities of performing such analyses. Unfortunately, the available data did not allow detailed analyses of potential sources of heterogeneity. In addition, we have reversed the definition of an event in <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> compared to prior versions of this review, which resulted in a high event rate, potentially introducing bias through the use of risk ratios as our effect measure. We felt the analysis of 'reversal of hepatorenal syndrome' was easier to interpret clinically than 'non-reversal'. This also obviated the need to perform a separate analysis for 'improvement in renal function'.</P>
<P>We did not search specifically for harms reported in quasi-randomised and observational studies, which is a weakness of this review that may bias our assessments of the balance between benefits and harms.</P>
<P>We did not search databases of regulatory authorities, and so may have overlooked unpublished trials. This could also have hampered our assessments of the balance between benefits and harms.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-05-31 12:28:58 +0100" MODIFIED_BY="[Empty name]">
<P>Three of the included trials found that baseline serum creatinine was an independent predictor of survival (<LINK REF="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TYPE="STUDY">Martín-Llahí 2008</LINK>; <LINK REF="STD-Neri-2008" TYPE="STUDY">Neri 2008</LINK>; <LINK REF="STD-Sanyal-2008" TYPE="STUDY">Sanyal 2008</LINK>). In our analyses, the baseline creatinine in the control groups of the trials on terlipressin plus albumin ranged from 194 to 362 µmol/L (2.2 to 4.1 mg/dL). All trials found similar baseline values for the treatment and control groups. In agreement with previous findings, our analyses suggest that the treatment effect was the largest in the trial with the lowest baseline serum creatinine (<LINK REF="STD-Solanki-2003" TYPE="STUDY">Solanki 2003</LINK>). This may suggest that treatment should be administered early and that a protracted deterioration in renal function impedes recovery. Inclusion of non-randomised, observational studies would have increased our ability to detect rare adverse events. However, we found no observational studies that reported adverse events to include in these analyses.</P>
<P>A number of meta-analyses have assessed the effect of terlipressin for hepatorenal syndrome (<LINK REF="REF-Fabrizi-2009" TYPE="REFERENCE">Fabrizi 2009</LINK>; <LINK REF="REF-Dobre-2010" TYPE="REFERENCE">Dobre 2010</LINK>; <LINK REF="REF-Sagi-2010" TYPE="REFERENCE">Sagi 2010</LINK>). The results concerning mortality are equivocal. One meta-analysis found that terlipressin increases survival among participants with type 1 hepatorenal syndrome (<LINK REF="REF-Sagi-2010" TYPE="REFERENCE">Sagi 2010</LINK>). The two remaining meta-analyses found no clear effect of terlipressin on survival, although only one performed a meta-analysis addressing this question (<LINK REF="REF-Fabrizi-2009" TYPE="REFERENCE">Fabrizi 2009</LINK>). In agreement with our findings, all reviews found that terlipressin seems to improve renal function but also increases the risk of cardiovascular and ischaemic adverse events. The differences between the conclusions in the different reviews are mainly related to the inclusion criteria. For example, one review only included placebo-controlled trials (<LINK REF="REF-Fabrizi-2009" TYPE="REFERENCE">Fabrizi 2009</LINK>). This decision is not clearly supported by previous evidence on the importance of bias control in RCTs (<LINK REF="REF-Gluud-2006" TYPE="REFERENCE">Gluud 2006</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>). Although lack of blinding may affect the risk of bias, there is no clear or consistent evidence to support the exclusion of open trials from meta-analyses since the effect of blinding is inconsistent across trials. The extent, as well as the effect, of bias associated with lack of blinding is unpredictable and does not support the a priori exclusion of trials based on this component alone.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-06-14 09:50:51 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<IMPLICATIONS_PRACTICE MODIFIED="2017-05-31 11:52:34 +0100" MODIFIED_BY="[Empty name]">
<P>This review includes RCTs evaluating people with cirrhosis and hepatorenal syndrome. The main body of evidence evaluated terlipressin and albumin for participants with type 1 hepatorenal syndrome. The number of RCTs evaluating terlipressin without albumin and the number of participants with type 2 hepatorenal syndrome were small. The analyses suggest a potential beneficial effect of terlipressin on mortality and hepatorenal syndrome, but also an increased risk of serious cardiovascular adverse events and gastrointestinal events such as diarrhoea.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-06-14 09:50:51 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We used the EPICOT format in the definition of implications for research (<LINK REF="REF-Brown-2006" TYPE="REFERENCE">Brown 2006</LINK>):</P>
<P>
<B>E</B>vidence (what is the current state of the evidence?): this review includes seven RCTs and found low-quality evidence that combined terlipressin and albumin has both beneficial and harmful effects in the management of people with type 1 hepatorenal syndrome. Additional research is needed to further evaluate the effect of the intervention in type 2 hepatorenal syndrome.</P>
<P>
<B>P</B>articipants (what is the population of interest?): the largest body of evidence evaluated people with cirrhosis and type 1 hepatorenal syndrome. Future RCTs should consider evaluating participants with hepatorenal syndrome defined using current guidelines.</P>
<P>
<B>I</B>nterventions (what are the interventions of interest?): the interventions assessed included terlipressin in doses ranging from 1 mg twice a day up to 2 mg six times a day for a median duration of 15 days (range 2 to 19 days).</P>
<P>
<B>C</B>omparisons (what are the comparisons of interest?): placebo or no intervention.</P>
<P>
<B>O</B>utcomes (what are the outcomes of interest?): RCTs should include an assessment of mortality, hepatorenal syndrome, and adverse events. Additional evidence evaluating the effect on health-related quality of life is also needed.</P>
<P>
<B>T</B>ime stamp (date of literature search): November 2016.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-05-31 12:29:02 +0100" MODIFIED_BY="[Empty name]">
<P>Thank you to the authors who provided additional information on the included trials. We also thank Sarah Klingenberg from the Cochrane Hepato-Biliary Group for performing the electronic searches.<BR/>
<BR/>Cochrane Review Group funding acknowledgement: The Danish State is the largest single funder of the Cochrane Hepato-Biliary Group through its investment in The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Denmark. Disclaimer: The views and opinions expressed in this review are those of the authors and do not necessarily reflect those of the Danish State or The Copenhagen Trial Unit.<BR/>
</P>
<P>Peer reviewers: Andrea Messori, Italy; Paolo Angeli, Italy.<BR/>Contact editor: Gennaro D'Amico, Italy.<BR/>Sign-off editor: Christian Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-06-14 10:06:59 +0100" MODIFIED_BY="[Empty name]">
<P>Andrew S Allegretti: served on a Scientific Advisory Board for Ferring Pharmaceuticals (makers of terlipressin in Europe) after the submission of this manuscript.<BR/>	Mads Israelsen: no conflicts of interest.<BR/>	Aleksander Krag: Served on a Scientific Advisory Board for Norgine, planned scientific meetings for Norgine and Intercept, and received funding for research from Norgine. Manol Jovani: no conflicts of interest.<BR/>	Alison H Goldin: no conflicts of interest.<BR/>	Allison R Schulman: no conflicts of interest.<BR/>	Rachel W Winter: no conflicts of interest.<BR/>	Lise Lotte Gluud: acted as investigator in studies funded by AbbVie, Intercept, Merck and Norgine, received funding for travel expenses and consultancy from Novo Nordisk, and for scientific presentations at meetings funded by Norgine and Eli Lily.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-05-31 12:29:06 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (AA and MI) updated the searches, listed potentially eligible trials, and extracted data. Four authors participated in the final selection of trials (AA, MI, AK, LG), and three conducted the analyses (AA, MI, LG). Three authors (AA, MI, LG) participated in the interpretation of data and revision of the review. All authors approved the final version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-06-14 09:51:00 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>We have updated the criteria for assessment of the outcome measures, bias control, and statistical analyses including the Trial Sequential Analysis.</LI>
<LI>Based on the latest criteria (described by the International Club of Ascites (<A HREF="http://www.icascites.org">www.icascites.org</A>)) and the recommendation of the Cochrane Hepato-Biliary Group, we have excluded urine output and creatinine clearance from our analyses.</LI>
<LI>We originally planned to include trials comparing different vasoactive drugs, but excluded these analyses based on review comments.</LI>
<LI>In keeping with updates to Cochrane review protocols, we changed the title and objectives to include the term "people with cirrhosis", though this did not affect the inclusion of studies.</LI>
<LI>We have changed the term "reversal of hepatorenal syndrome and improved renal function" to "number of participants who did not achieve reversal of hepatorenal syndrome", in order to be consistent with the other primary outcome (mortality), which is also framed in the negative. We removed "improved renal function", as it replicates the same analysis as "reversal of hepatorenal syndrome".</LI>
<LI>We have added calculations of number needed to treat for primary outcomes.</LI>
<LI>We have moved health-related quality of life to the secondary outcomes.</LI>
<LI>We did not perform Egger's test to assess the effect of small study size.</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-06-14 11:27:43 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDIES MODIFIED="2017-06-14 10:02:30 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<INCLUDED_STUDIES MODIFIED="2017-06-13 17:41:25 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Boyer-2016" MODIFIED="2017-05-31 12:15:45 +0100" MODIFIED_BY="[Empty name]" NAME="Boyer 2016" YEAR="2016">
<REFERENCE MODIFIED="2016-07-26 15:37:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyer TD, Medicis JJ, Pappas SC, Potenziano J, Jamil K</AU>
<TI>A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design</TI>
<SO>Open Access Journal of Clinical Trials</SO>
<YR>2012</YR>
<VL>4</VL>
<PG>39-49</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229671"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-31 12:15:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, et al</AU>
<TI>Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1</TI>
<SO>Gastroenterology</SO>
<YR>2016</YR>
<VL>150</VL>
<NO>7</NO>
<PG>1579-89.e2</PG>
<IDENTIFIERS MODIFIED="2016-02-22 14:26:21 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229672"/><IDENTIFIER TYPE="PUBMED" VALUE="26896734"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229670"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hadengue-1998" MODIFIED="2017-06-13 17:41:25 +0100" MODIFIED_BY="[Empty name]" NAME="Hadengue 1998" YEAR="1998">
<REFERENCE MODIFIED="2017-06-13 17:41:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hadengue A, Gadano A, Giostra E, Negro F, Moreau R, Valla D, et al</AU>
<TI>Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross-over study</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1995</YR>
<VL>22</VL>
<PG>165A</PG>
<IDENTIFIERS MODIFIED="2017-06-13 17:41:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-06-13 17:41:25 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229674"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-24 01:41:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al</AU>
<TI>Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome</TI>
<SO>Journal of Hepatology</SO>
<YR>1998</YR>
<VL>29</VL>
<PG>565-70</PG>
<IDENTIFIERS MODIFIED="2017-05-24 01:41:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229675"/><IDENTIFIER MODIFIED="2017-05-24 01:41:53 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="PMID: 9824265"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229673"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" MODIFIED="2017-05-24 01:42:52 +0100" MODIFIED_BY="[Empty name]" NAME="Martín-Llahí 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-05-24 01:42:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, et al</AU>
<TI>Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study</TI>
<SO>Gastroenterology</SO>
<YR>2008</YR>
<VL>134</VL>
<PG>1352-9</PG>
<IDENTIFIERS MODIFIED="2017-05-24 01:42:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229677"/><IDENTIFIER MODIFIED="2017-05-24 01:42:52 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ClinicalTrials.gov NCT00287664"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-13 11:39:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin-Llahi M, Pepin MN, Guevara M, Torre A, Monescillo A, Soriano G, et al</AU>
<TI>Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome</TI>
<SO>Journal of Hepatology</SO>
<YR>2007</YR>
<VL>46</VL>
<PG>S36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229678"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229676"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neri-2008" MODIFIED="2016-04-14 14:48:28 +0100" MODIFIED_BY="[Empty name]" NAME="Neri 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-04-14 14:48:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, et al</AU>
<TI>Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2008</YR>
<VL>53</VL>
<PG>830-5</PG>
<IDENTIFIERS MODIFIED="2008-07-17 10:00:06 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229680"/><IDENTIFIER MODIFIED="2008-07-17 10:00:06 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17939047"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229679"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pulvirenti-2008" MODIFIED="2016-11-18 15:05:22 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Pulvirenti 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-11-18 15:05:22 +0000" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pulvirenti D, Tsami A</AU>
<TI>Low doses of terlipressin and albumin in type I hepatorenal syndrome</TI>
<TO>Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I</TO>
<SO>Italian Journal of Medicine</SO>
<YR>2008</YR>
<VL>2</VL>
<PG>34-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229682"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-10-16 14:56:04 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229681"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanyal-2008" MODIFIED="2017-06-13 17:41:11 +0100" MODIFIED_BY="[Empty name]" NAME="Sanyal 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-11-18 15:05:34 +0000" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanyal A, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Teuber P</AU>
<TI>A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS)</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2006</YR>
<VL>44</VL>
<PG>694A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229684"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-24 01:44:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al</AU>
<TI>A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome</TI>
<SO>Gastroenterology</SO>
<YR>2008</YR>
<VL>134</VL>
<PG>1360-8</PG>
<IDENTIFIERS MODIFIED="2017-05-24 01:44:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229685"/><IDENTIFIER MODIFIED="2008-06-17 08:30:50 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18471513"/><IDENTIFIER MODIFIED="2017-05-24 01:44:57 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ClinicalTrials.gov NCT00089570"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-13 17:41:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanyal AJ, Boyer TD, Garcia-Tsao G, Blei AT, Teuber P; Terlipressin Study Group</AU>
<TI>Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2008</YR>
<VL>48</VL>
<PG>1071A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229686"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-11-18 15:05:53 +0000" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanyal AJ, Boyer TD, Teuber P</AU>
<TI>Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double-blind, placebo-controlled trial</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2007</YR>
<VL>46</VL>
<PG>565A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229687"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229683"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solanki-2003" MODIFIED="2017-05-24 02:06:25 +0100" MODIFIED_BY="[Empty name]" NAME="Solanki 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-05-24 02:06:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK</AU>
<TI>Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>152-6</PG>
<IDENTIFIERS MODIFIED="2017-05-24 02:06:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229689"/><IDENTIFIER MODIFIED="2017-05-24 02:06:25 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="PMID: 12542598"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229688"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2001" MODIFIED="2017-05-31 12:16:23 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-05-31 12:16:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang YZ , Dan ZL , Lin NZ , Lin M, Liang KH</AU>
<TI>Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome</TI>
<SO>Journal of Internal Intensive Medicine</SO>
<YR>2001</YR>
<VL>7</VL>
<PG>123-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229691"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229690"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zafar-2012" MODIFIED="2016-11-18 15:08:30 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Zafar 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-11-18 15:08:30 +0000" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zafar S, Haque I, UnTayyab G, Khan G, Chaudry N</AU>
<TI>Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2012</YR>
<VL>107</VL>
<PG>S175</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229693"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229692"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-06-13 17:44:27 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alessandria-2007" MODIFIED="2017-05-24 01:52:15 +0100" MODIFIED_BY="[Empty name]" NAME="Alessandria 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-04-09 01:57:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alessandria C, Marzano A, Ottobrelli A, Debernardi-Venon W, Todros L, Torrni M, et al</AU>
<TI>Noradrenaline vs terlipressin in hepatorenal syndrome: a prospective, randomized study</TI>
<SO>Journal of Hepatology</SO>
<YR>2006</YR>
<VL>44</VL>
<PG>S83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229695"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-24 01:52:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, et al</AU>
<TI>Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study</TI>
<SO>Journal of Hepatology</SO>
<YR>2007</YR>
<VL>47</VL>
<PG>499-505</PG>
<IDENTIFIERS MODIFIED="2017-05-24 01:52:15 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229696"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229694"/><IDENTIFIER TYPE="OTHER" VALUE="ClinicalTrials.gov NCT00370253"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angeli-2008" MODIFIED="2016-11-18 15:09:02 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Angeli 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-11-18 15:09:02 +0000" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angeli P, Fasolato S, Cavallin M, Maresio G, Callegaro A, Sticca A, et al</AU>
<TI>Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis: results of a controlled clinical study</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2008</YR>
<VL>48</VL>
<PG>378A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229698"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229697"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cavallin-2012" MODIFIED="2017-06-13 17:42:10 +0100" MODIFIED_BY="[Empty name]" NAME="Cavallin 2012" YEAR="2011">
<REFERENCE MODIFIED="2017-06-13 17:42:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavallin M, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, et al</AU>
<TI>Terlipressin and albumin vs midodrine plus octreotide in the treatment of hepatorenal syndrome in patients with cirrhosis: results of a controlled trial by the Italian Association for the Study of the Liver</TI>
<SO>Digestive and Liver Disease</SO>
<YR>2012</YR>
<VL>44</VL>
<PG>S10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229700"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229699"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cavallin-2015" MODIFIED="2016-11-18 15:09:43 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Cavallin 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-11-18 15:09:43 +0000" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, et al; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome</AU>
<TI>Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2015</YR>
<VL>62</VL>
<PG>567-74</PG>
<IDENTIFIERS MODIFIED="2015-12-10 12:03:07 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229702"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229701"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chelarescu-2003" MODIFIED="2017-01-31 13:22:01 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Chelarescu 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-01-31 13:22:01 +0000" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chelarescu D, Chelarescu O, Crumpie F, Staratan I</AU>
<TI>Captopril in low dose associated with octreotide in hepatorenal syndrome: a randomized study</TI>
<SO>Journal of Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<PG>S56</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229704"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229703"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Indrabi-2013" MODIFIED="2016-11-28 14:56:10 +0000" MODIFIED_BY="[Empty name]" NAME="Indrabi 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-11-28 14:56:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Indrabi RA, Zargar GJSA, Khan BA, Yattoo GN, Shah SH, Gulzar BM, et al</AU>
<TI>Noradrenaline is equally effective as terlipressin in reversal of type 1 hepatorenal syndrome: a randomized prospective study</TI>
<SO>Journal of Clinical and Experimental Hepatology</SO>
<YR>2013</YR>
<VL>3</VL>
<PG>S97</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5753302"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5753301"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nguyen_x002d_Tat-2015" MODIFIED="2017-05-31 12:16:56 +0100" MODIFIED_BY="[Empty name]" NAME="Nguyen-Tat 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-05-31 12:16:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nguyen-Tat M, Götz E, Scholz-Kreisel P, Ahrens J, Sivanathan V, Schattenberg J, et al</AU>
<TI>Response to terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome</TI>
<TO>Leberzirrhose und hepatorenales Syndrom: Das Ansprechen auf Terlipressin und Albumin ist mit besserem Überleben assoziiert</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>2015</YR>
<VL>140</VL>
<PG>21-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5753304"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-28 06:50:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5753303"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pomier-2003" MODIFIED="2016-11-18 15:10:34 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Pomier 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-11-18 15:10:34 +0000" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A</AU>
<TI>Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2003</YR>
<VL>38</VL>
<PG>238-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229706"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229705"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2008" MODIFIED="2016-11-18 15:21:05 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Sharma 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-04-09 02:00:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sharma P, Kumar A, Shrama BC, Sarin SK</AU>
<TI>An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2008</YR>
<VL>103</VL>
<PG>1689-97</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229708"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-11-18 15:21:05 +0000" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma P, Kumar A, Shrama BC, Sarin SK</AU>
<TI>Noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome: a randomized controlled trial</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2006</YR>
<VL>44</VL>
<PG>449A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229709"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229707"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Silawat-2011" MODIFIED="2016-11-18 15:10:54 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Silawat 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-11-18 15:10:54 +0000" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silawat FN, Shaikh MK, Lohana RK, Devrajani BR, Shah SZA, Ansari A</AU>
<TI>Efficacy of terlipressin and albumin in the treatment of hepatorenal syndrome</TI>
<SO>World Applied Sciences Journal</SO>
<YR>2011</YR>
<VL>12</VL>
<NO>11</NO>
<PG>1946-59</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229711"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229710"/><IDENTIFIER TYPE="OTHER" VALUE="ISSN 1818-4952"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wan-2014" MODIFIED="2017-06-13 17:44:27 +0100" MODIFIED_BY="[Empty name]" NAME="Wan 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-06-13 17:44:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wan S, Wan X, Zhu Q, Peng J</AU>
<TI>A comparative study of high- or low-dose terlipressin therapy in patients with cirrhosis and type 1 hepatorenal syndrome</TI>
<TO>&#39640;&#20302;&#21058;&#37327;&#29305;&#21033;&#21152;&#21387;&#32032;&#27835;&#30103;&#32925;&#30828;&#21270;&#21512;&#24182;1&#22411;&#32925;&#32958;&#32508;&#21512;&#24449;&#30340;&#27604;&#36739;</TO>
<SO>Zhonghua Gan Zang Bing Za Zhi</SO>
<YR>2014</YR>
<VL>21</VL>
<PG>35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5753306"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5753305"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-02-16 14:20:03 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2017-06-14 10:02:30 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01143246" MODIFIED="2017-06-14 10:02:30 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="NCT01143246" YEAR="3246">
<IDENTIFIERS MODIFIED="2011-06-15 11:46:00 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229712"/><IDENTIFIER MODIFIED="2011-06-15 11:46:00 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01143246"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-06-14 10:02:30 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2017-06-14 10:02:30 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<REFERENCE ID="REF-Angeli-2015" MODIFIED="2015-12-10 12:08:14 +0000" MODIFIED_BY="[Empty name]" NAME="Angeli 2015" TYPE="JOURNAL_ARTICLE">
<AU>Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al</AU>
<TI>Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites</TI>
<SO>Journal of Hepatology</SO>
<YR>2015</YR>
<VL>62</VL>
<PG>968-74</PG>
<IDENTIFIERS MODIFIED="2015-12-10 12:07:21 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="25638527"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arroyo-1996" MODIFIED="2016-11-18 15:11:55 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Arroyo 1996" TYPE="JOURNAL_ARTICLE">
<AU>Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al</AU>
<TI>Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1996</YR>
<VL>23</VL>
<PG>164-76</PG>
<IDENTIFIERS MODIFIED="2009-02-13 12:55:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2006" MODIFIED="2016-11-18 15:12:01 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Brown 2006" TYPE="JOURNAL_ARTICLE">
<AU>Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al</AU>
<TI>How to formulate research recommendations</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2006</YR>
<VL>333</VL>
<PG>804-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cardenas-2003" MODIFIED="2009-07-05 15:49:37 +0100" MODIFIED_BY="[Empty name]" NAME="Cardenas 2003" TYPE="JOURNAL_ARTICLE">
<AU>Cardenas A, Arroyo V</AU>
<TI>Hepatorenal syndrome</TI>
<SO>Annals of Hepatology</SO>
<YR>2003</YR>
<VL>2</VL>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dobre-2010" MODIFIED="2012-08-20 13:20:17 +0100" MODIFIED_BY="[Empty name]" NAME="Dobre 2010" TYPE="JOURNAL_ARTICLE">
<AU>Dobre M, Demirjian S, Sehgal AR, Navaneethan SD</AU>
<TI>Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis</TI>
<SO>International Urology and Nephrology</SO>
<YR>2011</YR>
<VL>43</VL>
<NO>1</NO>
<PG>175-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fabrizi-2009" MODIFIED="2016-11-18 15:12:14 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Fabrizi 2009" TYPE="JOURNAL_ARTICLE">
<AU>Fabrizi F, Dixit V, Messa P, Martin P</AU>
<TI>Terlipressin for hepatorenal syndrome: a meta-analysis of randomized trials</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>2009</YR>
<VL>32</VL>
<PG>133-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freeman-1982" MODIFIED="2009-07-05 15:49:37 +0100" MODIFIED_BY="[Empty name]" NAME="Freeman 1982" TYPE="JOURNAL_ARTICLE">
<AU>Freeman JG, Cobden I, Lishman AH, Record CO</AU>
<TI>Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>2</VL>
<PG>66-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Tsao-2008" MODIFIED="2016-11-18 15:12:42 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Garcia-Tsao 2008" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Tsao G, Parikh CR, Viola A</AU>
<TI>Acute kidney injury and cirrhosis</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2008</YR>
<VL>48</VL>
<PG>2064-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gines-1993" MODIFIED="2009-07-05 15:49:37 +0100" MODIFIED_BY="[Empty name]" NAME="Gines 1993" TYPE="JOURNAL_ARTICLE">
<AU>Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al</AU>
<TI>Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis</TI>
<SO>Gastroenterology</SO>
<YR>1993</YR>
<VL>105</VL>
<PG>229-36</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8514039"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gines-2003" MODIFIED="2009-07-05 15:49:37 +0100" MODIFIED_BY="[Empty name]" NAME="Gines 2003" TYPE="JOURNAL_ARTICLE">
<AU>Gines P, Guevara M, Arroyo V, Rodes J</AU>
<TI>Hepatorenal syndrome</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<PG>1819-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2017" MODIFIED="2017-01-31 13:23:57 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Gluud 2017" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL</AU>
<TI>Cochrane Hepato-Biliary Group</TI>
<SO>About Cochrane (Cochrane Review Groups (CRGs)) 2017, Issue 1. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro" MODIFIED="2017-06-14 10:02:30 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="GRADEpro" TYPE="COMPUTER_PROGRAM">
<AU>Brozek J, Oxman A, Schünemann H</AU>
<TI>GRADEpro</TI>
<YR>2008</YR>
<EN>3.2 for Windows</EN>
<PB>Grade Working Group</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-11-18 15:13:43 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S, editor(s)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hr_x00f3_bjartsson-2001" MODIFIED="2017-01-17 12:36:16 +0000" MODIFIED_BY="[Empty name]" NAME="Hróbjartsson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hróbjartsson A, Gøtzsche PC</AU>
<TI>Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<PG>1594-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2017-06-13 17:39:29 +0100" MODIFIED_BY="[Empty name]" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>Philadelphia (PA)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Israelsen-2015a" MODIFIED="2017-05-24 02:13:10 +0100" MODIFIED_BY="[Empty name]" NAME="Israelsen 2015a" TYPE="COCHRANE_PROTOCOL">
<AU>Israelsen, M, Krag A, Gluud LL</AU>
<TI>Terlipressin versus other vasoactive drugs for hepatorenal syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-11-18 15:15:33 +0000" MODIFIED_BY="Sarah  Klingenberg"><IDENTIFIER MODIFIED="2016-11-18 15:15:33 +0000" MODIFIED_BY="Sarah  Klingenberg" TYPE="DOI" VALUE="10.1002/14651858.CD011532"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Israelsen-2015b" MODIFIED="2017-06-13 17:40:28 +0100" MODIFIED_BY="[Empty name]" NAME="Israelsen 2015b" TYPE="JOURNAL_ARTICLE">
<AU>Israelsen ME, Gluud LL, Krag A</AU>
<TI>Acute kidney injury and hepatorenal syndrome in cirrhosis</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2015</YR>
<VL>30</VL>
<PG>236-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krag-2008" MODIFIED="2010-11-08 23:28:21 +0000" MODIFIED_BY="[Empty name]" NAME="Krag 2008" TYPE="JOURNAL_ARTICLE">
<AU>Krag A, Borup T, Møller S, Bendtsen F</AU>
<TI>Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome</TI>
<SO>Advances in Therapy</SO>
<YR>2008</YR>
<VL>25</VL>
<PG>1105-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moller-2004" MODIFIED="2017-05-24 02:23:58 +0100" MODIFIED_BY="[Empty name]" NAME="Moller 2004" TYPE="JOURNAL_ARTICLE">
<AU>Moller S, Henriksen JH</AU>
<TI>Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention?</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2004</YR>
<VL>20</VL>
<PG>31-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Obritsch-2004" MODIFIED="2012-08-20 13:20:17 +0100" MODIFIED_BY="[Empty name]" NAME="Obritsch 2004" TYPE="JOURNAL_ARTICLE">
<AU>Obritsch MD, Bestul DJ, Jung R, Fish DN, MacLaren R</AU>
<TI>The role of vasopressin in vasodilatory septic shock</TI>
<SO>Pharmacotherapy</SO>
<YR>2004</YR>
<VL>24</VL>
<PG>1050-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pasqualetti-1998" MODIFIED="2012-08-20 13:20:17 +0100" MODIFIED_BY="[Empty name]" NAME="Pasqualetti 1998" TYPE="JOURNAL_ARTICLE">
<AU>Pasqualetti P, Festuccia V, Collacciani A, Acitelli P, Casale R</AU>
<TI>Circadian rhythm of arginine vasopressin in hepatorenal syndrome</TI>
<SO>Nephron</SO>
<YR>1998</YR>
<VL>78</VL>
<PG>33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-11-18 15:16:31 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2016-11-18 15:18:50 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruiz-del-Arbol-2005" MODIFIED="2016-11-18 15:16:40 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Ruiz del Arbol 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al</AU>
<TI>Circulatory function and hepatorenal syndrome in cirrhosis</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2005</YR>
<VL>42</VL>
<PG>439-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sagi-2010" MODIFIED="2010-10-31 18:35:35 +0000" MODIFIED_BY="[Empty name]" NAME="Sagi 2010" TYPE="JOURNAL_ARTICLE">
<AU>Sagi SV, Mittal S, Kasturi KS, Sood GK</AU>
<TI>Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2010</YR>
<VL>25</VL>
<PG>880-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salerno-2007" MODIFIED="2009-07-05 15:49:37 +0100" MODIFIED_BY="[Empty name]" NAME="Salerno 2007" TYPE="JOURNAL_ARTICLE">
<AU>Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V</AU>
<TI>Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis</TI>
<SO>Gut</SO>
<YR>2007</YR>
<VL>56</VL>
<PG>1310-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovi_x0107_-2012" MODIFIED="2017-01-17 12:40:06 +0000" MODIFIED_BY="[Empty name]" NAME="Savovi&#263; 2012" TYPE="JOURNAL_ARTICLE">
<AU>Savovi&#263; J, Jones H, Altman D, Harris R, J&#369;ni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies</TI>
<SO>Health Technology Assessments</SO>
<YR>2012</YR>
<VL>16</VL>
<PG>1-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shawcross-2004" MODIFIED="2016-11-18 15:16:59 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Shawcross 2004" TYPE="JOURNAL_ARTICLE">
<AU>Shawcross DL, Davies NA, Mookerjee RP, Hayes PC, Williams R, Lee A, et al</AU>
<TI>Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>471-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-STATA" MODIFIED="2011-01-30 18:33:31 +0000" MODIFIED_BY="[Empty name]" NAME="STATA" TYPE="COMPUTER_PROGRAM">
<TI>STATA</TI>
<YR>2007</YR>
<PB>Stata Corp</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TSA-2011" MODIFIED="2016-11-18 15:17:28 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="TSA 2011" TYPE="COMPUTER_PROGRAM">
<TI>TSA - Trial Sequential Analysis</TI>
<YR>2011</YR>
<EN>0.9 Beta</EN>
<PB>Copenhagen Trial Unit</PB>
<CY>Copenhagen</CY>
<MD>www.ctu.dk/tsa/downloads.aspx</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2017-01-31 13:07:22 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-06-13 17:45:07 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Gluud-2006" MODIFIED="2016-11-18 14:28:57 +0000" MODIFIED_BY="Sarah  Klingenberg" NAME="Gluud 2006" TYPE="COCHRANE_REVIEW">
<AU>Gluud LL, Kjaer MS, Christensen E</AU>
<TI>Terlipressin for hepatorenal syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-04-14 17:05:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-04-14 17:05:35 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005162"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2010" MODIFIED="2017-06-13 17:45:07 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2010" TYPE="JOURNAL_ARTICLE">
<AU>Gluud LL, Christensen K, Christensen E, Krag A</AU>
<TI>Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>2</NO>
<PG>576-84</PG>
<IDENTIFIERS MODIFIED="2017-05-24 02:24:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-05-24 02:24:22 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/hep.23286"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-06-14 09:47:00 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-06-14 09:47:00 +0100" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Country of origin" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Inclusion period" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Proportion with type 1 hepatorenal syndrome">
<INCLUDED_CHAR MODIFIED="2017-05-31 12:05:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boyer-2016">
<CHAR_METHODS MODIFIED="2017-05-31 11:59:47 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, multicentre RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-14 15:46:46 +0100" MODIFIED_BY="[Empty name]">
<P>Participants had cirrhosis and type 1 hepatorenal syndrome based on the 2007 International Club of Ascites criteria.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-31 11:59:51 +0100" MODIFIED_BY="[Empty name]">
<P>Terlipressin/albumin versus placebo/albumin for a maximum of 14 days. The investigators discontinued treatment if serum creatinine was below 1.5 mg/dL at the initiation of renal replacement therapy or liver transplantation.</P>
<P>Terlipressin</P>
<UL>
<LI>1 mg 4 times daily increased to 2 mg 6 times daily in non-responders (participants without improved renal function).</LI>
</UL>
<P>Albumin</P>
<UL>
<LI>20 to 40 g/day.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-28 12:19:33 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of follow-up: 90 days</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-06-14 15:46:54 +0100" MODIFIED_BY="[Empty name]">
<P>United States and Canada</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-28 12:19:41 +0100" MODIFIED_BY="[Empty name]">
<P>October 2010 to February 2013</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-02-22 14:50:07 +0000" MODIFIED_BY="[Empty name]">
<P>100%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2017-05-31 12:05:13 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-31 12:29:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hadengue-1998">
<CHAR_METHODS MODIFIED="2017-05-31 12:00:06 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, single-centre RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-31 12:29:12 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mean age:</LI>
<UL>
<LI>terlipressin group: 53 years</LI>
<LI>placebo group: 53 years</LI>
</UL>
<LI>Proportion of men: 56%</LI>
<LI>Proportion with alcoholic liver disease: 78%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-31 12:00:09 +0100" MODIFIED_BY="[Empty name]">
<P>Terlipressin versus placebo</P>
<P>Terlipressin</P>
<UL>
<LI>1 mg twice daily for 2 days.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-28 10:14:51 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>Duration of follow-up: end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-11-28 10:14:48 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>France</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-11-28 10:14:47 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not described</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-03-09 12:48:36 +0000" MODIFIED_BY="[Empty name]">
<P>100%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2017-05-18 23:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>We did not include the trial in our analyses of hepatorenal syndrome because we did not have information about the outcome measure from the first period.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-31 12:29:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008">
<CHAR_METHODS MODIFIED="2017-05-31 12:00:17 +0100" MODIFIED_BY="[Empty name]">
<P>Open, multicentre RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-31 12:29:21 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mean age:</LI>
<UL>
<LI>terlipressin/albumin group: 59 years</LI>
<LI>albumin group: 52 years</LI>
</UL>
<LI>Proportion of men: 63%</LI>
<LI>Proportion with alcoholic liver disease: 72%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-31 12:00:23 +0100" MODIFIED_BY="[Empty name]">
<P>Terlipressin/albumin versus albumin for a maximum of 15 days</P>
<P>Terlipressin</P>
<UL>
<LI>1 mg 6 times daily. If no improvement in renal function was observed, the dose was increased to 2 mg 6 times daily.</LI>
</UL>
<P>Albumin</P>
<UL>
<LI>1 g/kg for 24 hours then 40 g/day adjusted according to the central venous pressure.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-28 10:13:59 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>Duration of follow-up: 3 months after treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-11-28 10:13:57 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>Spain</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2017-05-31 12:29:22 +0100" MODIFIED_BY="[Empty name]">
<P>January 2002 to February 2006</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-08-20 09:25:38 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>56%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2017-05-31 12:00:27 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-31 12:29:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neri-2008">
<CHAR_METHODS MODIFIED="2017-05-31 12:00:43 +0100" MODIFIED_BY="[Empty name]">
<P>Open, multicentre RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-31 12:29:26 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mean age:</LI>
<UL>
<LI>terlipressin and albumin group: 59 years</LI>
<LI>albumin group: 60 years</LI>
</UL>
<LI>Proportion of men: 40%</LI>
<LI>Proportion with alcoholic liver disease: 13%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-31 12:00:48 +0100" MODIFIED_BY="[Empty name]">
<P>Terlipressin/albumin versus albumin for 19 days</P>
<P>Terlipressin</P>
<UL>
<LI>1 mg 4 times daily for 5 days then 0.5 mg 4 times daily for 14 days.</LI>
</UL>
<P>Albumin</P>
<UL>
<LI>1 g/kg for 24 hours then 40 to 80 g/day.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-31 12:00:51 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of follow-up: 6 months after hospital discharge</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-11-28 10:12:54 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>Italy</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-11-28 10:12:52 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>December 2002 to December 2005</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-08-20 09:25:46 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>100%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2017-05-31 12:29:27 +0100" MODIFIED_BY="[Empty name]">
<P>Participants with recurrence of hepatorenal syndrome after the initial treatment received terlipressin and albumin.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-31 12:29:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pulvirenti-2008">
<CHAR_METHODS MODIFIED="2017-05-31 12:01:15 +0100" MODIFIED_BY="[Empty name]">
<P>Open, single-centre RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-31 12:29:31 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mean age:</LI>
<UL>
<LI>terlipressin group: 58 years</LI>
<LI>albumin group: 61 years</LI>
</UL>
<LI>Proportion of men: 37%</LI>
<LI>Proportion with alcoholic liver disease: 13%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-31 12:01:18 +0100" MODIFIED_BY="[Empty name]">
<P>Terlipressin/albumin versus albumin for a maximum of 15 days</P>
<P>Terlipressin</P>
<UL>
<LI>1 mg/hour for the first day, then 0.5 mg/8 hours for the next 12 days.</LI>
</UL>
<P>Albumin</P>
<UL>
<LI>1 g/kg/day for 5 days.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-28 10:11:48 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>Duration of follow-up: 180 days after treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-11-16 20:42:38 +0000" MODIFIED_BY="[Empty name]">
<P>Italy</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2015-11-16 20:43:33 +0000" MODIFIED_BY="[Empty name]">
<P>June 2004 to March 2006</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-11-16 20:44:00 +0000" MODIFIED_BY="[Empty name]">
<P>100%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2017-05-31 12:01:22 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-31 12:29:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanyal-2008">
<CHAR_METHODS MODIFIED="2017-05-31 12:01:35 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, multicentre RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-31 12:01:39 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mean age:</LI>
<UL>
<LI>terlipressin/albumin group: 51 years</LI>
<LI>placebo/albumin group: 53 years</LI>
</UL>
<LI>Proportion of men: 71%</LI>
<LI>Proportion with alcoholic liver disease: 36%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-31 12:01:42 +0100" MODIFIED_BY="[Empty name]">
<P>Terlipressin/albumin versus placebo/albumin for a maximum of 14 days</P>
<P>Terlipressin</P>
<UL>
<LI>1 mg 4 times daily increased to 2 mg 4 times daily if serum creatinine had not decreased by at least 30%.</LI>
</UL>
<P>Albumin</P>
<UL>
<LI>100 g for 24 hours then 25 g daily.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-28 10:10:31 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>Duration of follow-up: 6 months</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2017-05-31 12:29:33 +0100" MODIFIED_BY="[Empty name]">
<P>United States, Germany, and Russia</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-11-28 10:10:22 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>June 2004 to September 2006</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-08-20 09:25:52 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>100%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2017-05-31 12:01:47 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-31 12:29:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Solanki-2003">
<CHAR_METHODS MODIFIED="2017-05-31 12:01:58 +0100" MODIFIED_BY="[Empty name]">
<P>Open, single-centre RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-31 12:29:38 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mean age:</LI>
<UL>
<LI>terlipressin/albumin group: 51 years</LI>
<LI>albumin group: 52 years</LI>
</UL>
<LI>Proportion of men: 71%</LI>
<LI>Proportion with alcoholic liver disease: 33%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-31 12:02:04 +0100" MODIFIED_BY="[Empty name]">
<P>Terlipressin/albumin versus placebo/albumin for 15 days</P>
<P>Terlipressin</P>
<UL>
<LI>1 mg twice daily.</LI>
</UL>
<P>Albumin</P>
<UL>
<LI>20 g daily.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-28 10:08:59 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>Duration of follow-up: end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-11-28 10:08:56 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>India</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-11-28 10:08:54 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not described</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-10-31 10:09:37 +0000" MODIFIED_BY="[Empty name]">
<P>100%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2017-05-31 12:02:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-31 12:29:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2001">
<CHAR_METHODS MODIFIED="2017-05-31 12:02:19 +0100" MODIFIED_BY="[Empty name]">
<P>Open, single-centre RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-31 12:02:43 +0100" MODIFIED_BY="[Empty name]">
<P>Participant characteristics (n = 50) not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-28 10:08:23 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>Terlipressin versus no intervention for 15 days</P>
<P>Terlipressin</P>
<UL>
<LI>1 mg twice daily.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-31 12:29:41 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of follow-up: 15 days</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-11-28 10:08:27 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>China</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-11-28 10:08:28 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-02-18 16:29:55 +0000" MODIFIED_BY="[Empty name]">
<P>100%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2017-05-31 12:02:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-31 12:03:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zafar-2012">
<CHAR_METHODS MODIFIED="2017-05-31 12:03:10 +0100" MODIFIED_BY="[Empty name]">
<P>Open, multicentred RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-31 12:03:14 +0100" MODIFIED_BY="[Empty name]">
<P>Participant characteristics not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-31 12:03:14 +0100" MODIFIED_BY="[Empty name]">
<P>Terlipressin/albumin versus albumin for 10 days (range 8 to 12 days)</P>
<UL>
<LI>Terlipressin (1 mg/4 hourly).</LI>
<LI>Albumin (1 g/kg followed by 20 to 40 g/day).</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-11 12:50:54 +0000" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-11 12:43:22 +0000" MODIFIED_BY="[Empty name]">
<P>Pakistan</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-11 12:49:33 +0000" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-11 12:48:45 +0000" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2017-05-31 12:03:17 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>RCTs: randomised clinical trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-05-31 12:05:36 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-05-31 12:03:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alessandria-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 12:03:27 +0100" MODIFIED_BY="[Empty name]">
<P>RCT on noradrenaline/albumin versus terlipressin/albumin for hepatorenal syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 12:03:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Angeli-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 12:03:27 +0100" MODIFIED_BY="[Empty name]">
<P>RCT comparing different modes of administering terlipressin/albumin for hepatorenal syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 12:03:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cavallin-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 12:03:27 +0100" MODIFIED_BY="[Empty name]">
<P>RCT on terlipressin/albumin versus midodrine/octreotide/albumin for hepatorenal syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 12:03:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cavallin-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 12:03:27 +0100" MODIFIED_BY="[Empty name]">
<P>RCT comparing terlipressin versus midodrine/octreotide for people with hepatorenal syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 12:03:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chelarescu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 12:03:26 +0100" MODIFIED_BY="[Empty name]">
<P>RCT comparing captopril/octreotide versus octreotide published in abstract form.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 12:03:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Indrabi-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 12:03:26 +0100" MODIFIED_BY="[Empty name]">
<P>RCT on noradrenalin/albumin versus terlipressin/albumin for hepatorenal syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-28 07:07:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nguyen_x002d_Tat-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-28 07:07:20 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study on terlipressin for hepatorenal syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-09 19:38:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pomier-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-09 19:38:37 +0000" MODIFIED_BY="[Empty name]">
<P>Cross-over trial on octreotide for hepatorenal syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 12:03:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 12:03:33 +0100" MODIFIED_BY="[Empty name]">
<P>RCT on noradrenalin/albumin versus terlipressin/albumin for hepatorenal syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 12:03:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silawat-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 12:03:33 +0100" MODIFIED_BY="[Empty name]">
<P>RCT on dopamine versus terlipressin/albumin for hepatorenal syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 12:05:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wan-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 12:05:36 +0100" MODIFIED_BY="[Empty name]">
<P>RCT comparing low and high-dose of terlipressin for hepatorenal syndrome type 1.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-02-16 14:20:03 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-05-31 12:29:43 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2017-05-31 12:29:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01143246">
<CHAR_STUDY_NAME MODIFIED="2017-05-31 12:29:42 +0100" MODIFIED_BY="[Empty name]">
<P>A placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-05-31 12:03:44 +0100" MODIFIED_BY="[Empty name]">
<P>Study type: interventional<BR/>Study design: allocation: randomised<BR/>Endpoint classification: safety/efficacy study<BR/>Intervention model: parallel assignment<BR/>Masking: double-blind (participant, investigator)<BR/>Primary purpose: treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-31 12:03:44 +0100" MODIFIED_BY="[Empty name]">
<P>Cirrhosis, ascites, and hepatorenal syndrome type 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-31 12:03:44 +0100" MODIFIED_BY="[Empty name]">
<P>Drug: terlipressin<BR/>Blinded terlipressin reconstituted with 5 mL of sterile 0.9% sodium chloride solution for injection will be administered intravenously as a slow bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (4 mg/day).<BR/>Other name: Lucassin</P>
<P>Drug: placebo<BR/>Lyophilised mannitol reconstituted with 5 mL of sterile 0.9% sodium chloride solution administered intravenously as a slow bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (4 mg/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-31 12:03:44 +0100" MODIFIED_BY="[Empty name]">
<P>Confirmed hepatorenal syndrome reversal: the percentage of participants with 2 serum creatinine values of &#8804; 133 µmol/L (1.5 mg/dL) at least 48 hours apart, on treatment, and without intervening renal replacement therapy or liver transplant.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2017-05-31 12:29:43 +0100" MODIFIED_BY="[Empty name]">
<P>September 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-16 20:12:34 +0100" MODIFIED_BY="[Empty name]">
<P>Diane Stebbins diane.stebbins@ikaria.com<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-11-28 10:06:57 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<P>Estimated enrolment: 180<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-05-31 12:29:42 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-05-31 12:29:39 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:15:26 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Boyer-2016">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:14:35 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Hadengue-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:13:50 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:12:39 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Neri-2008">
<DESCRIPTION>
<P>Computer-generated list of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:29:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pulvirenti-2008">
<DESCRIPTION>
<P>Computer-generated list of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:10:10 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sanyal-2008">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:29:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solanki-2003">
<DESCRIPTION>
<P>Random-number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:08:10 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-11 12:51:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zafar-2012">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-05-31 12:04:51 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:15:20 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Boyer-2016">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:14:33 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Hadengue-1998">
<DESCRIPTION>
<P>Identical coded drug containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:13:44 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:12:30 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Neri-2008">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:11:33 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Pulvirenti-2008">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:10:04 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sanyal-2008">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:04:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solanki-2003">
<DESCRIPTION>
<P>Centralised randomisation through an independent statistician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:08:09 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-11 12:51:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zafar-2012">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-05-31 12:29:34 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1" REF_IDS="CMP-001.03 CMP-001.04 CMP-001.06">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-22 14:32:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boyer-2016">
<DESCRIPTION>
<P>Blinding of participants and personnel using placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-05-31 12:29:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hadengue-1998">
<DESCRIPTION>
<P>Blinding of participants and personnel achieved through double-blinding using terlipressin placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-11-28 10:13:42 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008">
<DESCRIPTION>
<P>No blinding of participants or personnel (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-11-28 10:12:27 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Neri-2008">
<DESCRIPTION>
<P>No blinding of participants or personnel (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-11-28 10:11:23 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Pulvirenti-2008">
<DESCRIPTION>
<P>No blinding of participants or personnel (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-05-31 12:29:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanyal-2008">
<DESCRIPTION>
<P>Blinding of participants and personnel achieved through double-blinding using terlipressin placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-05-31 12:04:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solanki-2003">
<DESCRIPTION>
<P>The authors state that the trial is single-blind, but do not describe the method of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-11-28 10:07:57 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Yang-2001">
<DESCRIPTION>
<P>No blinding of participants or personnel (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-11-28 10:07:33 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Zafar-2012">
<DESCRIPTION>
<P>No blinding of participants or personnel (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-02-18 14:31:21 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-05-31 12:29:35 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1" REF_IDS="CMP-001.03 CMP-001.04 CMP-001.06">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-28 10:15:18 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Boyer-2016">
<DESCRIPTION>
<P>Blinding of outcome assessors using placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-05-31 12:29:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hadengue-1998">
<DESCRIPTION>
<P>Blinding of outcome assessment achieved through double-blinding using terlipressin placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-28 10:13:40 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008">
<DESCRIPTION>
<P>No blinding of outcome assessment (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-28 10:12:25 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Neri-2008">
<DESCRIPTION>
<P>No blinding of outcome assessment (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-28 10:11:22 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Pulvirenti-2008">
<DESCRIPTION>
<P>No blinding of outcome assessment (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-05-31 12:29:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanyal-2008">
<DESCRIPTION>
<P>Blinding of outcome assessment achieved through double-blinding using terlipressin placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-05-31 12:02:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solanki-2003">
<DESCRIPTION>
<P>The authors state that the trial is single-blind, but do not describe the method of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-28 10:07:56 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Yang-2001">
<DESCRIPTION>
<P>No blinding of outcome assessment (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-28 10:07:32 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Zafar-2012">
<DESCRIPTION>
<P>No blinding of outcome assessment (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-05-31 12:29:36 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-22 14:49:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boyer-2016">
<DESCRIPTION>
<P>All participants included in the analyses based on the intention-to-treat principle. Information about clinical outcomes was available for all participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-31 12:00:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hadengue-1998">
<DESCRIPTION>
<P>The trial report states that the analyses excluded 3 participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-31 12:29:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008">
<DESCRIPTION>
<P>No losses to follow-up, and all participants included in the analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-28 10:12:23 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Neri-2008">
<DESCRIPTION>
<P>No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-28 10:11:18 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Pulvirenti-2008">
<DESCRIPTION>
<P>No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-31 12:29:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanyal-2008">
<DESCRIPTION>
<P>Intention-to-treat analyses including all participants randomised are reported. No outcomes reported after censoring.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-31 12:04:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solanki-2003">
<DESCRIPTION>
<P>There were no losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-28 10:07:54 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2001">
<DESCRIPTION>
<P>Unclear reporting of losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-26 15:27:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zafar-2012">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-05-31 12:29:40 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:05:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boyer-2016">
<DESCRIPTION>
<P>Clinically relevant outcomes reported as described in the protocol and online trial registration.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:29:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hadengue-1998">
<DESCRIPTION>
<P>Clinically relevant outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:00:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008">
<DESCRIPTION>
<P>Clinically relevant outcome measures reported.</P>
<P>Primary outcome measures:</P>
<UL>
<LI>mortality after 3 months; and</LI>
<LI>improvement in renal function.</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:01:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neri-2008">
<DESCRIPTION>
<P>Clinically relevant outcome measures reported.</P>
<P>Primary outcome measure: resolution of hepatorenal syndrome defined as normalisation of creatinine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:29:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pulvirenti-2008">
<DESCRIPTION>
<P>Clinically relevant outcome measures reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:29:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanyal-2008">
<DESCRIPTION>
<P>Clinically relevant outcome measures reported.</P>
<P>Primary outcome measure: treatment success at day 14 defined as normalisation of serum creatinine on 2 measurements with at least 48-hour intervals and no dialysis, death, or recurrence of hepatorenal syndrome type 1 before day 15</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:29:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solanki-2003">
<DESCRIPTION>
<P>Clinically relevant outcome measures reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:02:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yang-2001">
<DESCRIPTION>
<P>Clinically relevant outcome measures reported.</P>
<P>Primary outcome measure: reversal of hepatorenal syndrome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-11 12:53:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zafar-2012">
<DESCRIPTION>
<P>Clinically relevant outcome measures reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2017-05-31 12:29:42 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>For-profit funding</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:05:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boyer-2016">
<DESCRIPTION>
<P>Ikaria Therapeutics LLC funded the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:29:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hadengue-1998">
<DESCRIPTION>
<P>The trial received funding from Ferring S.A., France.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-17 16:24:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008">
<DESCRIPTION>
<P>The trial did not receive funding from pharmaceutical companies (reported in the discussion).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:00:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neri-2008">
<DESCRIPTION>
<P>Funding not reported. Email requesting information about funding sent 17 February 2016.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:01:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pulvirenti-2008">
<DESCRIPTION>
<P>Funding not reported. Email requesting information about funding sent 17 February 2016.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:09:41 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Sanyal-2008">
<DESCRIPTION>
<P>Industry funding (Orphan Therapeutics)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:29:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solanki-2003">
<DESCRIPTION>
<P>Funding not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:29:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2001">
<DESCRIPTION>
<P>Funding not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-11 12:51:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zafar-2012">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-05-31 12:29:16 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:05:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boyer-2016">
<DESCRIPTION>
<P>No other biases identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:29:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hadengue-1998">
<DESCRIPTION>
<P>No other biases identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-03-15 11:19:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008">
<DESCRIPTION>
<P>No other biases identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:12:13 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Neri-2008">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:11:01 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Pulvirenti-2008">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:09:32 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sanyal-2008">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:04:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solanki-2003">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:07:45 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Yang-2001">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:07:24 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Zafar-2012">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2017-05-31 12:29:23 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Overall risk of bias (mortality)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:05:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boyer-2016">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:29:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hadengue-1998">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:29:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008">
<DESCRIPTION>
<P>Low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:01:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neri-2008">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-23 06:12:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pulvirenti-2008">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-23 06:11:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sanyal-2008">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:04:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Solanki-2003">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:07:44 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Yang-2001">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:07:26 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Zafar-2012">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2017-05-31 12:04:51 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Overall risk of bias (non-mortality outcomes)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-23 06:11:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boyer-2016">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-23 06:12:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hadengue-1998">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-23 06:12:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-23 06:12:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neri-2008">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-23 06:12:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pulvirenti-2008">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-23 06:11:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sanyal-2008">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-31 12:04:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Solanki-2003">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:07:43 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Yang-2001">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-28 10:07:26 +0000" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Zafar-2012">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-06-14 09:45:52 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-06-14 09:45:52 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" READONLY="YES">
<TITLE MODIFIED="2017-04-25 15:08:29 +0100" MODIFIED_BY="[Empty name]">Terlipressin versus placebo or no intervention for hepatorenal syndrome</TITLE>
<TABLE COLS="7" ROWS="22">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Terlipressin versus placebo or no intervention for hepatorenal syndrome. Administration of albumin allowed if administered to both the intervention and comparison group</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>people with hepatorenal syndrome<BR/>
<B>Setting: </B>hospital<BR/>
<B>Intervention: </B>terlipressin alone or terlipressin plus albumin</P>
<P>
<B>Comparison: </B>placebo or no intervention or albumin</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="BOTTOM">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="BOTTOM">
<P>Risk with placebo or no intervention</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="BOTTOM">
<P>Risk with terlipressin</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Mortality</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 0.85 (0.73 to 0.98)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>534<BR/>(9 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Downgraded because of i) clinical heterogeneity and ii) the results of the Trial Sequential Analysis</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>688 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>536 per 1000<BR/>(433 to 660)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>625 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>488 per 1000<BR/>(394 to 600)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Hepatorenal syndrome</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 0.63 (0.48 to 0.82)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>510<BR/>(7 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Downgraded because of i) clinical heterogeneity and ii) all trials are judged as 'high risk of bias'.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>879 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>510 per 1000<BR/>(431 to 606)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>875 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>507 per 1000<BR/>(429 to 604)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Serious adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.91 (0.68 to 1.21)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>534 (9 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Downgraded because of i) clinical heterogeneity and ii) all RCTs are judged as high risk of bias.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>85 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>212 per 1000<BR/>(131 to 344)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Serious cardiovascular adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 7.26 (1.70 to 31.05)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>234<BR/>(4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Downgraded because of i) clinical heterogeneity and ii) all RCTs are judged as high risk of bias</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>16 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>111 per 1000</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Abdominal pain</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.54 (0.97 to 2.43)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>294 (4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Downgraded because of i) clinical heterogeneity and ii) all RCTs are judged as high risk of bias</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>149 per 1000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>229 per 1000</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Diarrhoea</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 5.76 (2.19 to 15.15)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>240 (2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Downgraded because of i) clinical heterogeneity and ii) all RCTs are judged as high risk of bias</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>33 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>190 per 1000</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect.<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Not confirmed in analyses of randomised clinical trials (RCTs) with a low risk of bias.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-10-28 16:07:41 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-06-13 17:44:05 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2017-06-13 17:44:05 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Terlipressin alone or with albumin versus no intervention or albumin</NAME>
<DICH_OUTCOME CHI2="8.169563007948474" CI_END="0.9818304277201616" CI_START="0.7274295634648608" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8451109272947515" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="164" I2="14.316102425681304" I2_Q="5.433255317362937" ID="CMP-001.01" LOG_CI_END="-0.007963512889851225" LOG_CI_START="-0.13820905276061476" LOG_EFFECT_SIZE="-0.07308628282523298" METHOD="MH" MODIFIED="2017-02-06 14:31:52 +0000" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.31788002638913726" P_Q="0.30379692103657163" P_Z="0.02783262954634966" Q="1.0574541857774291" RANDOM="YES" SCALE="153.15" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.006678463348016363" TOTALS="YES" TOTAL_1="266" TOTAL_2="268" WEIGHT="100.0" Z="2.199637427024398">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No Intervenion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.165860164389379" CI_END="0.9830497334456061" CI_START="0.6260446429802471" DF="5" EFFECT_SIZE="0.7844953915777846" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="125" I2="30.224705962761938" ID="CMP-001.01.01" LOG_CI_END="-0.007424510230298471" LOG_CI_START="-0.20339469632842272" LOG_EFFECT_SIZE="-0.10540960327936058" MODIFIED="2016-02-22 14:44:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.20859455535536497" P_Z="0.03499000504015634" STUDIES="7" TAU2="0.02289527674796911" TOTAL_1="218" TOTAL_2="220" WEIGHT="61.2553120039324" Z="2.108474050728877">
<NAME>Type 1 hepatorenal syndrome</NAME>
<DICH_DATA CI_END="1.303615600828631" CI_START="0.696066807742995" EFFECT_SIZE="0.9525773195876288" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" LOG_CI_END="0.11514954917976344" LOG_CI_START="-0.15734907527203973" LOG_EFFECT_SIZE="-0.021099763046138177" MODIFIED="2016-02-22 14:44:57 +0000" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.16006704089293483" STUDY_ID="STD-Boyer-2016" TOTAL_1="97" TOTAL_2="99" VAR="0.02562145758022047" WEIGHT="18.12172206765453"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-17 16:09:32 +0000" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.0" STUDY_ID="STD-Hadengue-1998" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9011912747216885" CI_START="0.3623321945119133" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="21" LOG_CI_END="-0.04518302174022607" LOG_CI_START="-0.44089307563236285" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2010-10-31 14:17:44 +0000" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.232442044452599" STUDY_ID="STD-Neri-2008" TOTAL_1="26" TOTAL_2="26" VAR="0.054029304029304004" WEIGHT="9.641767687332175"/>
<DICH_DATA CI_END="1.6662261811165466" CI_START="0.4741994008644479" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.2217339541797036" LOG_CI_START="-0.3240389990744662" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2015-11-16 07:39:20 +0000" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Pulvirenti-2008" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="5.347618224857793"/>
<DICH_DATA CI_END="1.2394914332944782" CI_START="0.6744043120371784" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" LOG_CI_END="0.09324352950174815" LOG_CI_START="-0.17107966156248744" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2010-10-31 15:49:39 +0000" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.1552647508520297" STUDY_ID="STD-Sanyal-2008" TOTAL_1="56" TOTAL_2="56" VAR="0.024107142857142855" WEIGHT="19.01311236062758"/>
<DICH_DATA CI_END="0.9677412506003884" CI_START="0.372000263269397" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="-0.014240746470540135" LOG_CI_START="-0.4294567527621726" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2011-06-16 20:43:33 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.24389993744808436" STUDY_ID="STD-Solanki-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.059487179487179465" WEIGHT="8.846436984322144"/>
<DICH_DATA CI_END="2.100712467573603" CI_START="0.007675952208988312" EFFECT_SIZE="0.12698412698412698" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.32236661295248636" LOG_CI_START="-2.1148677378757625" LOG_EFFECT_SIZE="-0.8962505624616381" MODIFIED="2011-06-16 21:19:41 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="1.431643522181124" STUDY_ID="STD-Yang-2001" TOTAL_1="8" TOTAL_2="7" VAR="2.0496031746031744" WEIGHT="0.2846546791381792"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07621210218030497" CI_END="1.141690023195329" CI_START="0.7462799960358251" DF="1" EFFECT_SIZE="0.9230495252067201" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="39" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.05754820593309335" LOG_CI_START="-0.12709819944578668" LOG_EFFECT_SIZE="-0.03477499675634661" MODIFIED="2016-03-11 12:55:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7824978468090634" P_Z="0.4603616494902185" STUDIES="2" TAU2="0.0" TOTAL_1="48" TOTAL_2="48" WEIGHT="38.7446879960676" Z="0.7382514819617769">
<NAME>Type 1 or 2 hepatorenal syndrome</NAME>
<DICH_DATA CI_END="1.2159776518570424" CI_START="0.6583624422684838" EFFECT_SIZE="0.8947368421052632" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.08492559322260776" LOG_CI_START="-0.18153495237171782" LOG_EFFECT_SIZE="-0.04830467957455503" MODIFIED="2016-02-18 16:31:58 +0000" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.15652024348308013" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TOTAL_1="23" TOTAL_2="23" VAR="0.02449858662000269" WEIGHT="18.77439303812095"/>
<DICH_DATA CI_END="1.2757824587404616" CI_START="0.7074090052084654" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.10577662656142792" LOG_CI_START="-0.1503294159837324" LOG_EFFECT_SIZE="-0.022276394711152253" MODIFIED="2016-03-11 12:55:46 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.15043795713638372" STUDY_ID="STD-Zafar-2012" TOTAL_1="25" TOTAL_2="25" VAR="0.022631578947368426" WEIGHT="19.97029495794665"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.708659249297697" CI_END="1.0083052516912214" CI_START="0.6652303483819895" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8189964919692518" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="102" I2="22.16545308385976" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.003592029189118522" LOG_CI_START="-0.17702794611189362" LOG_EFFECT_SIZE="-0.08671795846138755" METHOD="MH" MODIFIED="2017-06-13 17:44:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.26023420165447375" P_Q="1.0" P_Z="0.05983499535544201" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.016819529795597397" TOTALS="YES" TOTAL_1="254" TOTAL_2="256" WEIGHT="100.0" Z="1.8820075145498882">
<NAME>Mortality in randomised clinical trials evaluating terlipressin and albumin</NAME>
<GROUP_LABEL_1>Terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No Intervenion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.248656991253922" CI_START="0.01402562085443456" EFFECT_SIZE="0.3401360544217687" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9163832444569596" LOG_CI_START="-1.853077905281274" LOG_EFFECT_SIZE="-0.4683473304121573" MODIFIED="2016-03-11 12:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="1.6267951884100265" STUDY_ID="STD-Boyer-2016" TOTAL_1="97" TOTAL_2="99" VAR="2.6464625850340138" WEIGHT="0.4226584816290863"/>
<DICH_DATA CI_END="5.173959327437209" CI_START="0.5919064697242088" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7138230103992698" LOG_CI_START="-0.22774691302668085" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2016-02-17 17:18:52 +0000" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.5530828338666934" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TOTAL_1="23" TOTAL_2="23" VAR="0.3059006211180124" WEIGHT="3.4880337395018053"/>
<DICH_DATA CI_END="0.9011912747216885" CI_START="0.3623321945119133" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="21" LOG_CI_END="-0.04518302174022607" LOG_CI_START="-0.44089307563236285" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2012-04-09 16:49:46 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.232442044452599" STUDY_ID="STD-Neri-2008" TOTAL_1="26" TOTAL_2="26" VAR="0.054029304029304004" WEIGHT="15.88817647423503"/>
<DICH_DATA CI_END="1.6662261811165466" CI_START="0.4741994008644479" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.2217339541797036" LOG_CI_START="-0.3240389990744662" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2015-12-09 20:28:10 +0000" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Pulvirenti-2008" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="9.412074549530915"/>
<DICH_DATA CI_END="1.2394914332944782" CI_START="0.6744043120371784" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" LOG_CI_END="0.09324352950174815" LOG_CI_START="-0.17107966156248744" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2012-04-09 16:49:46 +0100" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.1552647508520297" STUDY_ID="STD-Sanyal-2008" TOTAL_1="56" TOTAL_2="56" VAR="0.024107142857142855" WEIGHT="27.504282704702522"/>
<DICH_DATA CI_END="0.9677412506003884" CI_START="0.372000263269397" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="-0.014240746470540135" LOG_CI_START="-0.4294567527621726" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2012-04-09 16:49:46 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.24389993744808436" STUDY_ID="STD-Solanki-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.059487179487179465" WEIGHT="14.751766723845046"/>
<DICH_DATA CI_END="1.2757824587404616" CI_START="0.7074090052084654" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.10577662656142792" LOG_CI_START="-0.1503294159837324" LOG_EFFECT_SIZE="-0.022276394711152253" MODIFIED="2016-07-26 13:40:25 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.15043795713638372" STUDY_ID="STD-Zafar-2012" TOTAL_1="25" TOTAL_2="25" VAR="0.022631578947368426" WEIGHT="28.533007326555595"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.494269781213244" CI_END="0.8186376044697435" CI_START="0.4846768081514847" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6299005168811761" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="224" I2="75.43365717476564" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.08690830972910311" LOG_CI_START="-0.31454776082769864" LOG_EFFECT_SIZE="-0.20072803527840094" METHOD="MH" MODIFIED="2017-04-25 15:09:54 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.7885673955408965E-4" P_Q="0.6390721841269744" P_Z="5.472064115279561E-4" Q="0.8954758178432195" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08397828362158809" TOTALS="YES" TOTAL_1="254" TOTAL_2="256" WEIGHT="100.0" Z="3.4565161524902175">
<NAME>Hepatorenal syndrome</NAME>
<GROUP_LABEL_1>Terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No Intervenion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="24.398849682295726" CI_END="0.8679872732856114" CI_START="0.4699673468809935" DF="5" EFFECT_SIZE="0.6386905948520822" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="196" I2="79.50723060674416" ID="CMP-001.03.01" LOG_CI_END="-0.06148664254511167" LOG_CI_START="-0.3279323156005319" LOG_EFFECT_SIZE="-0.19470947907282177" MODIFIED="2016-02-22 14:41:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.8195637685525234E-4" P_Z="0.004176013296265935" STUDIES="6" TAU2="0.09414886329305179" TOTAL_1="223" TOTAL_2="226" WEIGHT="79.31396351521715" Z="2.8645506759789567">
<NAME>Type 1 hepatorenal syndrome</NAME>
<DICH_DATA CI_END="1.0484562535191655" CI_START="0.8172763076537125" EFFECT_SIZE="0.925677295612563" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="86" LOG_CI_END="0.020550314389742252" LOG_CI_START="-0.08763109083330672" LOG_EFFECT_SIZE="-0.03354038822178225" MODIFIED="2016-02-22 14:41:08 +0000" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.06354629293461138" STUDY_ID="STD-Boyer-2016" TOTAL_1="97" TOTAL_2="99" VAR="0.00403813134573144" WEIGHT="20.314521087378353"/>
<DICH_DATA CI_END="1.0721604327013499" CI_START="0.49423420249363664" EFFECT_SIZE="0.7279411764705882" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.03025977586397303" LOG_CI_START="-0.30606720340930826" LOG_EFFECT_SIZE="-0.1379037137726676" MODIFIED="2016-02-18 16:39:09 +0000" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.19756013247052315" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TOTAL_1="17" TOTAL_2="18" VAR="0.039030005941770654" WEIGHT="14.535697750419436"/>
<DICH_DATA CI_END="0.5350911488794825" CI_START="0.10594333791979083" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="21" LOG_CI_END="-0.2715722327756828" LOG_CI_START="-0.9749263480201181" LOG_EFFECT_SIZE="-0.6232492903979004" MODIFIED="2015-11-16 07:43:47 +0000" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.4131536889536032" STUDY_ID="STD-Neri-2008" TOTAL_1="26" TOTAL_2="26" VAR="0.1706959706959707" WEIGHT="7.020777670205903"/>
<DICH_DATA CI_END="0.8008434869347125" CI_START="0.13874260442124223" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.09645235208343395" LOG_CI_START="-0.857790157355891" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-11-16 07:46:20 +0000" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Pulvirenti-2008" TOTAL_1="15" TOTAL_2="15" VAR="0.2" WEIGHT="6.296295952938603"/>
<DICH_DATA CI_END="0.9335968645138509" CI_START="0.6107337264268651" EFFECT_SIZE="0.7551020408163265" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="49" LOG_CI_END="-0.02984061553875661" LOG_CI_START="-0.21414809638428073" LOG_EFFECT_SIZE="-0.1219943559615187" MODIFIED="2015-11-16 07:44:28 +0000" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.10826312658540503" STUDY_ID="STD-Sanyal-2008" TOTAL_1="56" TOTAL_2="56" VAR="0.011720904578047434" WEIGHT="18.683662333259647"/>
<DICH_DATA CI_END="0.9677412506003884" CI_START="0.372000263269397" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="-0.014240746470540135" LOG_CI_START="-0.4294567527621726" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2015-11-16 07:44:55 +0000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.24389993744808436" STUDY_ID="STD-Solanki-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.059487179487179465" WEIGHT="12.46300872101521"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0834355946543177" CI_START="0.14010639528673774" DF="0" EFFECT_SIZE="0.38961038961038963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.03480309958053474" LOG_CI_START="-0.8535420404861735" LOG_EFFECT_SIZE="-0.4093694704528194" MODIFIED="2016-02-18 16:39:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07085725635073309" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="5" WEIGHT="5.0186599734749855" Z="1.8063911924986933">
<NAME>Type 2 hepatorenal syndrome</NAME>
<DICH_DATA CI_END="1.0834355946543177" CI_START="0.14010639528673774" EFFECT_SIZE="0.38961038961038963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.03480309958053474" LOG_CI_START="-0.8535420404861735" LOG_EFFECT_SIZE="-0.4093694704528194" MODIFIED="2016-02-18 16:39:36 +0000" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.5218183326545478" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TOTAL_1="6" TOTAL_2="5" VAR="0.27229437229437226" WEIGHT="5.0186599734749855"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9165402524823316" CI_START="0.4640612473947418" DF="0" EFFECT_SIZE="0.6521739130434783" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="-0.03784845700064021" LOG_CI_START="-0.333424696923183" LOG_EFFECT_SIZE="-0.18563657696191163" MODIFIED="2016-03-14 08:31:00 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.013819945907159474" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="15.667376511307863" Z="2.4619096931065303">
<NAME>Type 1 or 2 hepatorenal syndrome</NAME>
<DICH_DATA CI_END="0.9165402524823316" CI_START="0.4640612473947418" EFFECT_SIZE="0.6521739130434783" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="-0.03784845700064021" LOG_CI_START="-0.333424696923183" LOG_EFFECT_SIZE="-0.18563657696191163" MODIFIED="2016-03-14 08:31:00 +0000" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.17362294645648624" STUDY_ID="STD-Zafar-2012" TOTAL_1="25" TOTAL_2="25" VAR="0.030144927536231887" WEIGHT="15.667376511307863"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.78846729287399" CI_END="1.210533009362481" CI_START="0.6800591186392498" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9073224407181648" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="155" I2="70.5739763986522" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.0829766364778901" LOG_CI_START="-0.16745333173083538" LOG_EFFECT_SIZE="-0.042238347626472626" METHOD="MH" MODIFIED="2017-05-31 11:40:53 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0012410921088861215" P_Q="1.0" P_Z="0.5085173899400872" Q="0.0" RANDOM="YES" SCALE="509.64" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10800786900415264" TOTALS="YES" TOTAL_1="266" TOTAL_2="268" WEIGHT="100.00000000000001" Z="0.6611480303776581">
<NAME>Serious adverse events, total number</NAME>
<GROUP_LABEL_1>Terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No Intervenion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.303615600828631" CI_START="0.696066807742995" EFFECT_SIZE="0.9525773195876288" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" LOG_CI_END="0.11514954917976344" LOG_CI_START="-0.15734907527203973" LOG_EFFECT_SIZE="-0.021099763046138177" MODIFIED="2017-05-31 11:40:53 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.16006704089293483" STUDY_ID="STD-Boyer-2016" TOTAL_1="97" TOTAL_2="99" VAR="0.02562145758022047" WEIGHT="16.193697448435245"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-07-26 15:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.0" STUDY_ID="STD-Hadengue-1998" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.5360377716276976" CI_START="1.4165771460294163" EFFECT_SIZE="2.238095238095238" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.5485168954592109" LOG_CI_START="0.15124023094438555" LOG_EFFECT_SIZE="0.3498785632017982" MODIFIED="2016-07-26 15:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.2333622792872139" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TOTAL_1="23" TOTAL_2="23" VAR="0.05445795339412362" WEIGHT="13.319434530917329"/>
<DICH_DATA CI_END="0.9011912747216885" CI_START="0.3623321945119133" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="21" LOG_CI_END="-0.04518302174022607" LOG_CI_START="-0.44089307563236285" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2016-07-26 15:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.232442044452599" STUDY_ID="STD-Neri-2008" TOTAL_1="26" TOTAL_2="26" VAR="0.054029304029304004" WEIGHT="13.35466945290807"/>
<DICH_DATA CI_END="1.6662261811165466" CI_START="0.4741994008644479" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.2217339541797036" LOG_CI_START="-0.3240389990744662" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2016-07-26 15:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Pulvirenti-2008" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="10.266130156310943"/>
<DICH_DATA CI_END="1.2394914332944782" CI_START="0.6744043120371784" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" LOG_CI_END="0.09324352950174815" LOG_CI_START="-0.17107966156248744" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2016-07-26 15:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.1552647508520297" STUDY_ID="STD-Sanyal-2008" TOTAL_1="56" TOTAL_2="56" VAR="0.024107142857142855" WEIGHT="16.379311135492816"/>
<DICH_DATA CI_END="0.9677412506003884" CI_START="0.372000263269397" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="-0.014240746470540135" LOG_CI_START="-0.4294567527621726" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2016-07-26 15:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.24389993744808436" STUDY_ID="STD-Solanki-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.059487179487179465" WEIGHT="12.919503617788841"/>
<DICH_DATA CI_END="2.100712467573603" CI_START="0.007675952208988312" EFFECT_SIZE="0.12698412698412698" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.32236661295248636" LOG_CI_START="-2.1148677378757625" LOG_EFFECT_SIZE="-0.8962505624616381" MODIFIED="2016-07-26 15:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="1.431643522181124" STUDY_ID="STD-Yang-2001" TOTAL_1="8" TOTAL_2="7" VAR="2.0496031746031744" WEIGHT="1.002939288504731"/>
<DICH_DATA CI_END="1.2757824587404616" CI_START="0.7074090052084654" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.10577662656142792" LOG_CI_START="-0.1503294159837324" LOG_EFFECT_SIZE="-0.022276394711152253" MODIFIED="2016-07-26 15:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.15043795713638372" STUDY_ID="STD-Zafar-2012" TOTAL_1="25" TOTAL_2="25" VAR="0.022631578947368426" WEIGHT="16.56431436964203"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.976368125117768" CI_END="1.4687813420267535" CI_START="0.8391517179444509" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1101938508416025" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="45" I2="39.90532334134095" I2_Q="55.87481647310314" ID="CMP-001.05" LOG_CI_END="0.16695714703643538" LOG_CI_START="-0.07615951198504395" LOG_EFFECT_SIZE="0.045398817525695724" METHOD="MH" MODIFIED="2017-02-06 14:33:02 +0000" MODIFIED_BY="Dimitrinka Nikolova" NO="5" P_CHI2="0.09158720678482035" P_Q="0.04519123464911867" P_Z="0.46417183668077433" Q="11.33139762909362" RANDOM="YES" SCALE="513.32" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.18522535382522792" TOTALS="SUB" TOTAL_1="358" TOTAL_2="360" WEIGHT="600.0" Z="0.7319946535067189">
<NAME>Serious adverse events, types</NAME>
<GROUP_LABEL_1>Terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No Intervenion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.14735939198547005" CI_END="31.047488835170984" CI_START="1.6962958281306122" DF="3" EFFECT_SIZE="7.257115527882431" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="1.4920264795808362" LOG_CI_START="0.2295015939826846" LOG_EFFECT_SIZE="0.8607640367817604" MODIFIED="2016-06-20 15:47:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.985603156729209" P_Z="0.007528210667179553" STUDIES="4" TAU2="0.0" TOTAL_1="117" TOTAL_2="117" WEIGHT="100.00000000000001" Z="2.672527932754803">
<NAME>Cardovascular adverse events</NAME>
<DICH_DATA CI_END="188.12904084289215" CI_START="0.6431755536405884" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.274455841293656" LOG_CI_START="-0.1916704709772061" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2016-02-18 17:04:37 +0000" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="1.4486148033500308" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TOTAL_1="23" TOTAL_2="23" VAR="2.0984848484848486" WEIGHT="26.208928175129724"/>
<DICH_DATA CI_END="129.11288787863575" CI_START="0.3795128496084703" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1109695951340917" LOG_CI_START="-0.420773515105578" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2016-02-18 17:04:37 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="1.4871584352852965" STUDY_ID="STD-Neri-2008" TOTAL_1="26" TOTAL_2="26" VAR="2.211640211640211" WEIGHT="24.86798638452528"/>
<DICH_DATA CI_END="132.45797781714737" CI_START="0.3699286430874132" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1220781205617074" LOG_CI_START="-0.4318820405331937" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2016-02-18 17:04:37 +0000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="1.5002088409338348" STUDY_ID="STD-Sanyal-2008" TOTAL_1="56" TOTAL_2="56" VAR="2.25062656641604" WEIGHT="24.4372120596263"/>
<DICH_DATA CI_END="94.3366757334742" CI_START="0.2650082781232565" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.974680568368818" LOG_CI_START="-0.5767405596967805" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2016-02-18 17:04:37 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="1.4987174003640065" STUDY_ID="STD-Solanki-2003" TOTAL_1="12" TOTAL_2="12" VAR="2.2461538461538457" WEIGHT="24.4858733807187"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.173959327437209" CI_START="0.5919064697242088" DF="0" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.7138230103992698" LOG_CI_START="-0.22774691302668085" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2016-02-18 17:07:45 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3116280172763881" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="1.0118118908573899">
<NAME>Circulatory overload</NAME>
<DICH_DATA CI_END="5.173959327437209" CI_START="0.5919064697242088" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7138230103992698" LOG_CI_START="-0.22774691302668085" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2016-02-18 17:04:37 +0000" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.5530828338666934" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TOTAL_1="23" TOTAL_2="23" VAR="0.3059006211180124" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0543385040884483" CI_START="0.21634430915836506" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.3126720061284497" LOG_CI_START="-0.6648545242398122" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2016-02-18 17:07:45 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.48010460313185666" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.7061343401317748">
<NAME>Gastrointestinal bleeding</NAME>
<DICH_DATA CI_END="2.0543385040884483" CI_START="0.21634430915836506" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3126720061284497" LOG_CI_START="-0.6648545242398122" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2016-02-18 17:04:37 +0000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.5742039227726821" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TOTAL_1="23" TOTAL_2="23" VAR="0.32971014492753625" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4656309452514036" CI_START="0.6823000041313042" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="0.1660246260904549" LOG_CI_START="-0.16602462609045493" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-18 17:07:45 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.0">
<NAME>Hepatic encephalopathy</NAME>
<DICH_DATA CI_END="1.4656309452514036" CI_START="0.6823000041313042" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.1660246260904549" LOG_CI_START="-0.16602462609045493" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-18 17:04:37 +0000" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.19504737440137349" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TOTAL_1="23" TOTAL_2="23" VAR="0.03804347826086957" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8066771094953936" CI_END="4.596514437598624" CI_START="0.8407243961070807" DF="1" EFFECT_SIZE="1.9658081861533645" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" I2="0.0" ID="CMP-001.05.05" LOG_CI_END="0.6624286285688076" LOG_CI_START="-0.07534635005998762" LOG_EFFECT_SIZE="0.29354113925440994" MODIFIED="2016-02-23 15:22:53 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3691045465988737" P_Z="0.11884601857846827" STUDIES="2" TAU2="0.0" TOTAL_1="149" TOTAL_2="151" WEIGHT="100.00000000000001" Z="1.5596356005154588">
<NAME>Respiratory distress/acidosis</NAME>
<DICH_DATA CI_END="4.252443267487495" CI_START="0.7211227504865048" EFFECT_SIZE="1.7511520737327189" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6286385283324658" LOG_CI_START="-0.14199080279590456" LOG_EFFECT_SIZE="0.24332386276828064" MODIFIED="2016-02-23 15:22:53 +0000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.45267148378151617" STUDY_ID="STD-Boyer-2016" TOTAL_1="93" TOTAL_2="95" VAR="0.20491147222895947" WEIGHT="91.6551293849216"/>
<DICH_DATA CI_END="132.45797781714737" CI_START="0.3699286430874132" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1220781205617074" LOG_CI_START="-0.4318820405331937" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2016-02-18 17:04:37 +0000" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="1.5002088409338348" STUDY_ID="STD-Sanyal-2008" TOTAL_1="56" TOTAL_2="56" VAR="2.25062656641604" WEIGHT="8.344870615078419"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4260366107861049" CI_START="0.3944499010371978" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" I2="0.0" ID="CMP-001.05.06" LOG_CI_END="0.15413067534633929" LOG_CI_START="-0.40400814856293915" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2016-02-18 17:08:07 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.38023066284457774" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.877471387175914">
<NAME>Bacterial inflections</NAME>
<DICH_DATA CI_END="1.4260366107861049" CI_START="0.3944499010371978" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.15413067534633929" LOG_CI_START="-0.40400814856293915" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2016-02-18 17:04:37 +0000" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.3278535079960469" STUDY_ID="STD-Mart_x00ed_n_x002d_Llah_x00ed_-2008" TOTAL_1="23" TOTAL_2="23" VAR="0.10748792270531399" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.20382919435598" CI_END="2.591761099164235" CI_START="1.2604920019076393" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8074551547277378" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="63" I2="37.51246233992328" I2_Q="46.08135904277718" ID="CMP-001.06" LOG_CI_END="0.41359496706877796" LOG_CI_START="0.10054009432948327" LOG_EFFECT_SIZE="0.25706753069913063" METHOD="MH" MODIFIED="2017-02-06 14:33:16 +0000" MODIFIED_BY="Dimitrinka Nikolova" NO="6" P_CHI2="0.08372679294687813" P_Q="0.11535350191320481" P_Z="0.0012869213564778246" Q="7.418584610048798" RANDOM="YES" SCALE="509.64" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2211767150902726" TOTALS="SUB" TOTAL_1="549" TOTAL_2="555" WEIGHT="500.0" Z="3.2188804304894516">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>Terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No Intervenion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.8330444487625055" CI_END="2.6818111934269493" CI_START="0.5838348546959058" DF="4" EFFECT_SIZE="1.251293270355226" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="37" I2="17.23643259634836" ID="CMP-001.06.01" LOG_CI_END="0.4284281991161839" LOG_CI_START="-0.23370998137566976" LOG_EFFECT_SIZE="0.09735910887025707" MODIFIED="2017-01-05 16:44:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3048613611201699" P_Z="0.5643609248820698" STUDIES="5" TAU2="0.1831774419331798" TOTAL_1="202" TOTAL_2="204" WEIGHT="100.0" Z="0.5763762083946636">
<NAME>Total number</NAME>
<DICH_DATA CI_END="1.336027358136312" CI_START="0.6127075911456528" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="35" LOG_CI_END="0.12581535137753935" LOG_CI_START="-0.21274673893971993" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2017-01-05 16:44:30 +0000" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.19887304776173392" STUDY_ID="STD-Boyer-2016" TOTAL_1="93" TOTAL_2="95" VAR="0.0395504891260409" WEIGHT="67.92001658753253"/>
<DICH_DATA CI_END="219.53128267328708" CI_START="0.7698219494827567" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.341496414894147" LOG_CI_START="-0.11360971028047342" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2016-02-17 17:24:52 +0000" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="1.442141490898892" STUDY_ID="STD-Neri-2008" TOTAL_1="26" TOTAL_2="26" VAR="2.0797720797720793" WEIGHT="6.684941324121766"/>
<DICH_DATA CI_END="6.20048286508611" CI_START="0.16127776203218527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-17 17:24:52 +0000" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.9309493362512627" STUDY_ID="STD-Pulvirenti-2008" TOTAL_1="15" TOTAL_2="15" VAR="0.8666666666666667" WEIGHT="14.409458173961205"/>
<DICH_DATA CI_END="72.10286053406111" CI_START="0.12482167743883672" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8579524948097836" LOG_CI_START="-0.9037099853704584" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2016-02-17 17:24:52 +0000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="1.6222142113076252" STUDY_ID="STD-Sanyal-2008" TOTAL_1="56" TOTAL_2="56" VAR="2.631578947368421" WEIGHT="5.374420617552115"/>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2016-02-17 17:24:52 +0000" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Solanki-2003" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="5.611163296832377"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5654795019688946" CI_END="2.434958656894618" CI_START="0.9678642784626627" DF="3" EFFECT_SIZE="1.5351578106311168" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="22" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.3864915917375276" LOG_CI_START="-0.014185538608219268" LOG_EFFECT_SIZE="0.18615302656465418" MODIFIED="2017-02-06 14:30:27 +0000" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.9042875391330136" P_Z="0.0685790145177788" STUDIES="4" TAU2="0.0" TOTAL_1="146" TOTAL_2="148" WEIGHT="99.99999999999999" Z="1.8211831923874264">
<NAME>Abdominal pain</NAME>
<DICH_DATA CI_END="2.496733756933559" CI_START="0.9403544810313517" EFFECT_SIZE="1.532258064516129" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="20" LOG_CI_END="0.3973722331565296" LOG_CI_START="-0.026708401575341847" LOG_EFFECT_SIZE="0.18533191579059388" MODIFIED="2017-01-05 16:43:29 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.2491070640744992" STUDY_ID="STD-Boyer-2016" TOTAL_1="93" TOTAL_2="95" VAR="0.062054329371816645" WEIGHT="89.26726458608991"/>
<DICH_DATA CI_END="70.41836692752118" CI_START="0.12780756488237435" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84768594912681" LOG_CI_START="-0.8934434396874849" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2017-01-05 16:43:26 +0000" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Neri-2008" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="2.136633520659298"/>
<DICH_DATA CI_END="6.20048286508611" CI_START="0.16127776203218527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-11-16 20:34:34 +0000" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.9309493362512627" STUDY_ID="STD-Pulvirenti-2008" TOTAL_1="15" TOTAL_2="15" VAR="0.8666666666666667" WEIGHT="6.3916387370149925"/>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-10-31 14:33:24 +0000" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Solanki-2003" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="2.2044631562357835"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.34278665287792" CI_START="0.2516539030393281" DF="0" EFFECT_SIZE="4.999999999999999" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="1.9971363381737377" LOG_CI_START="-0.5991963295017001" LOG_EFFECT_SIZE="0.6989700043360187" MODIFIED="2017-01-05 16:48:23 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2912877682685008" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.0553008494084533">
<NAME>Chest pain</NAME>
<DICH_DATA CI_END="99.34278665287792" CI_START="0.2516539030393281" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9971363381737377" LOG_CI_START="-0.5991963295017001" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="137" O_E="0.0" SE="1.5250986610465322" STUDY_ID="STD-Neri-2008" TOTAL_1="26" TOTAL_2="26" VAR="2.3259259259259255" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.10286053406111" CI_START="0.12482167743883672" DF="0" EFFECT_SIZE="3.0000000000000004" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="1.8579524948097836" LOG_CI_START="-0.9037099853704584" LOG_EFFECT_SIZE="0.4771212547196625" MODIFIED="2016-02-17 17:25:15 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4982599788180675" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="56" WEIGHT="100.0" Z="0.6772300976099492">
<NAME>Livedo reticularis</NAME>
<DICH_DATA CI_END="72.10286053406111" CI_START="0.12482167743883672" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8579524948097836" LOG_CI_START="-0.9037099853704584" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-02-11 14:42:15 +0000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="1.6222142113076252" STUDY_ID="STD-Sanyal-2008" TOTAL_1="56" TOTAL_2="56" VAR="2.631578947368421" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.01948599374015911" CI_END="15.154535585028336" CI_START="2.186399033326454" DF="1" EFFECT_SIZE="5.756202042459707" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="4" I2="0.0" ID="CMP-001.06.05" LOG_CI_END="1.1805426318319854" LOG_CI_START="0.3397294266698404" LOG_EFFECT_SIZE="0.760136029250913" MODIFIED="2017-02-06 14:31:02 +0000" MODIFIED_BY="Dimitrinka Nikolova" NO="5" P_CHI2="0.8889821791904435" P_Z="3.943960489602177E-4" STUDIES="2" TAU2="0.0" TOTAL_1="119" TOTAL_2="121" WEIGHT="100.0" Z="3.5438055243096938">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="15.678610735710317" CI_START="2.013256522376509" EFFECT_SIZE="5.618279569892473" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" LOG_CI_END="1.1953075777014042" LOG_CI_START="0.30389911475690884" LOG_EFFECT_SIZE="0.7496033462291565" MODIFIED="2017-01-05 16:49:28 +0000" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.5236177436766527" STUDY_ID="STD-Boyer-2016" TOTAL_1="93" TOTAL_2="95" VAR="0.2741755414930288" WEIGHT="88.97039971094217"/>
<DICH_DATA CI_END="129.11288787863575" CI_START="0.3795128496084703" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1109695951340917" LOG_CI_START="-0.420773515105578" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2017-01-05 16:49:48 +0000" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="1.4871584352852965" STUDY_ID="STD-Neri-2008" TOTAL_1="26" TOTAL_2="26" VAR="2.211640211640211" WEIGHT="11.029600289057825"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-06-14 09:44:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-05-31 12:17:57 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAMLCAYAAABkdBFYAABFxElEQVR42u3db6Qd597H/0NVRUSF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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-05-31 12:29:43 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgments about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAaQAAAJjCAIAAADMK/LzAAAo2klEQVR42u3dz24USZfG4ZKQEAsv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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-06-14 09:44:58 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAFLCAMAAAAwDHIBAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Adjusted Boundaries Sketch.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2017-06-14 09:44:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial Sequential Analysis of eight randomised clinical trials (525 participants) evaluating terlipressin versus placebo or no intervention for people with hepatorenal syndrome on mortality. Data from <LINK REF="STD-Hadengue-1998" TYPE="STUDY">Hadengue 1998</LINK> is not included due to lack of events. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of mortality of 61.5%, and a model variance -based heterogeneity correction of 30%. The risk ratio is 0.85 (95% confidence interval 0.70 to 1.02). The cumulative Z-curve (blue line) does not cross the diversity-adjusted trial monitoring boundary for benefit.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAz0AAAJTCAIAAACtg++8AABj3UlEQVR42uy9D0xU+Z7oSS446EUH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</FILE>
</FIGURE>
<FIGURE FILENAME="Adjusted Boundaries Sketch.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2017-06-14 09:44:36 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial Sequential Analysis of seven randomised clinical trials (510 participants) evaluating terlipressin versus placebo/no intervention for people with hepatorenal syndrome on lack of reversal of hepatorenal syndrome. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of lack of reversal of hepatorenal syndrome of 88%, and a heterogeneity correction of 70%. The risk ratio is 0.64 (95% confidence interval 0.46 to 0.89). The cumulative Z-curve (blue line) crosses the diversity-adjusted trial monitoring boundary for benefit during the fourth trial.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAz0AAAJTCAIAAACtg++8AABmxUlEQVR42uy9DUxU6bqgSw660a1u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</FILE>
</FIGURE>
<FIGURE FILENAME="Adjusted Boundaries Sketch.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2017-06-14 09:44:34 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial Sequential Analysis of four randomised clinical trials (234 participants) evaluating terlipressin versus placebo or no intervention for people with hepatorenal syndrome on cardiovascular adverse events. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of cardiovascular adverse events of 15%, and a heterogeneity correction of 20%. The risk ratio is 7.26 (95% confidence interval 1.70 to 31.05). The diversity-adjusted trial monitoring boundary for harm is not included in the figure due to insufficient information. The estimated required information size is 4831 participants. Accordingly, with an accrued number of participants of 234, only 4.8% of the required number of participants has been achieved.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAz0AAAJTCAIAAACtg++8AAAt8ElEQVR42u3dD2icdcLg8bLd3JiL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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-06-13 17:42:59 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2017-06-13 17:42:59 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-11-18 14:53:29 +0000" MODIFIED_BY="Sarah  Klingenberg">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2017-06-13 17:42:59 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Timespan</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>November 2016</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(terlipressin* OR glypressin* OR vasoconstric*) AND 'hepatorenal syndrom*'</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2016, Issue 11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor Vasoconstrictor Agents explode all trees</P>
<P>#2 terlipressin* OR glypressin* OR vasoconstric*</P>
<P>#3 (#1 OR #2)</P>
<P>#4 MeSH descriptor Hepatorenal Syndrome explode all trees</P>
<P>#5 hepatorenal syndrom*</P>
<P>#6 (#4 OR #5)</P>
<P>#7 (#3 AND #4)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (OvidSP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1946 to November 2016</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Vasoconstrictor Agents/</P>
<P>2. (terlipressin* or glypressin* or vasoconstric*).mp. [mp=title, original title, abstract, name of substance word, subject heading word]</P>
<P>3. 1 or 2</P>
<P>4. exp Hepatorenal Syndrome/</P>
<P>5. hepatorenal syndrom*.mp. [mp=title, original title, abstract, name of substance word, subject heading word]</P>
<P>6. 4 or 5</P>
<P>7. 6 and 3</P>
<P>8. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, original title, abstract, name of substance word, subject heading word]</P>
<P>9. 8 and 7</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Embase (OvidSP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1974 to November 2016</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Terlipressin/</P>
<P>2. exp Vasoconstrictor Agent/</P>
<P>3. (terlipressin* or glypressin* or vasoconstric*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>4. 1 or 3 or 2</P>
<P>5. exp Hepatorenal Syndrome/</P>
<P>6. hepatorenal syndrom*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>7. 6 or 5</P>
<P>8. 4 and 7</P>
<P>9. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>10. 8 and 9</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded (Web of Science)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to November 2016</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 5 #4 AND #3</P>
<P># 4 TS=(random* or blind* or placebo* or meta-analysis)</P>
<P># 3 #1 AND #2</P>
<P># 2 TS=(hepatorenal syndrom*)</P>
<P># 1 TS=(terlipressin* or glypressin* or vasoconstric*)</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;9 randomised clinical trials included in quantitative synthesis (meta-analysis)&lt;/span&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;9 randomised clinical trials included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;25 references assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;199 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;619 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;3 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;174 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;10 references to randomised trials on people with hepatorenal syndrome excluded because they did not evaluate the intervention comparisons assessed in the present review&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>